King of Prussia, PA, 13 December, 2011 – Greenphire, the leading provider of payment technologies for the clinical trials industry, today announced that it has been chosen by AlwaysOn as one of the Venture Summit Mid-Atlantic 100 winners. Inclusion in the Venture Summit Mid-Atlantic 100 signifies leadership amongst its peers and game-changing approaches and technologies that are likely to disrupt existing markets and entrenched players. Greenphire was specially selected by the AlwaysOn editorial team and industry experts spanning the globe based on a set of five criteria: innovation, market potential, commercialization, stakeholder value and media buzz.
Greenphire and the Venture Summit Mid-Atlantic 100 companies were honored at the IMPACT Venture Summit Mid-Atlantic event, November 29th and 30th, 2011, at the Ritz Carlton in Philadelphia, PA.
This two-day executive event featured CEO presentations and high-level debates on the most promising emerging technologies and new entrepreneurial opportunities on the East Coast. The Greater Philadelphia Alliance for Capital and Technologies (PACT) annual venture conference, IMPACT 2011, is the most established venture conference in the northeast. For over 20 years, IMPACT has been showcasing the best and most promising investment opportunities in the technology, life sciences and clean technology sectors.
“The Venture Summit Mid-Atlantic 100 winners are transforming the mid-Atlantic region’s technology community through innovation and creativity,” said Tony Perkins, founder and editor at AlwaysOn. “The companies represent some of the highest-growth opportunities in the mid-Atlantic private company marketplace across all industry sectors, including digital media and entertainment, on-demand computing as well as greentech and the life sciences.”
The Venture Summit Mid-Atlantic 100 winners were selected from among thousands of mid-Atlantic technology companies nominated by investors, bankers, journalists and greentech industry insiders. The AlwaysOn editorial team conducted a rigorous three-month selection process to finalize the 2011 list.
Greenphire is the leading provider of payment and communication technology solutions in the clinical trials industry. The firm was founded by Sam Whitaker and John Samar in 2008 with the vision of creating a globally scalable technology platform to allow pharmaceutical and medical device developers and clinical research sites to electronically deliver payments to investigators, vendors and trial participants. Since then, Greenphire’s technologies have been implemented to support over 60,000 clinical trial participants across 6,000 studies at 1,200 clinical trial sites.
"We're thrilled and honored to be included in AlwaysOn's Venture Summit Mid-Atlantic 100,” said Greenphire CEO Samuel Whitaker. “Greenphire's unique clinical payment solutions are a perfect fit with AlwaysOn's focus on technological innovation, and this recognition is extremely valuable as we continue to establish the Greenphire brand as the leader in developing cutting-edge clinical technology platforms."
A full list of all the Venture Summit Mid-Atlantic 100 winners can be found on the AlwaysOn website at:http://www.aonetwork.com/AOStory/Announcing-2011-Venture-Summit-Mid-Atlantic-100-Top-Private-Companies
About Greenphire
Greenphire’s clinical payment and communication solutions take a patient-centric and site-centric approach to driving data integrity and data completeness for sponsor, CRO, research university, and clinical research site clients. Greenphire’s web-based technologies are designed to improve the clinical experience for patients and sites, drive positive patient behavior, increase patient retention and compliance, and significantly reduce site and study team administration associated with patient payments and communication. Greenphire’s strategy is driven by the philosophy that empowered, satisfied patients and sites will deliver more consistent and better quality clinical data, which will in turn benefit both site coordinators and study teams. Learn more about Greenphire’s innovative clinical solutions at www.greenphire.com.
About AlwaysOn
AlwaysOn is the leading business media brand networking the Global Silicon Valley. AlwaysOn helped ignite the social media revolution in early 2003 when it launched the AlwaysOn network. In 2004, it became the first media brand to socially network its online readers and event attendees. AlwaysOn’s preeminent executive event series includes the Silicon Valley Innovation Summit, OnMedia, OnHollywood, Venture Summit Mid-Atlantic, OnDemand, Venture Summit Silicon Valley, OnMobile, and GoingGreen Silicon Valley. The AlwaysOn network and live event series continue to lead the industry by empowering its readers, event participants, sponsors, and advertisers like no other media brand.
For further information on Greenphire and its innovative solutions please email: sales@greenphire.com, call +1 215-609-4640 or visit www.greenphire.com.
For further press information please contact Celine Callender, The Scott Partnership, 1 Whiteside, Station Road, Holmes Chapel, Cheshire CW4 8AA, United Kingdom. Phone +44 1477 539539, Fax +44 1477 539540, Email greenphire@scottpr.com
Wednesday 14 December 2011
Friday 9 December 2011
Novozymes expands collaboration with Upperton Limited to offer customers new albumin conjugation solution
Conjugating Recombumin® Flex to drugs offers the opportunity to dramatically enhance patient lives and drive down healthcare costs.
NOTTINGHAM, UK – December 8, 2011 – Novozymes Biopharma, part of Novozymes A/S, a world leader in bioinnovation, has announced that it has expanded its partnership with Nottingham-based research and development company, Upperton Limited, to offer customers a new albumin conjugation solution. By linking drugs to Novozymes’ new Recombumin® Flex recombinant human albumin (rAlbumin), using conjugation, their pharmacokinetic and pharmacodynamic properties can be dramatically enhanced. As a result, manufacturers can benefit from the ability to tailor and control the half-life of drugs to fit patients’ medical needs.
“Novozymes is delighted to unveil Recombumin Flex along with our new conjugation solution in partnership with Upperton Limited,” says Dave Mead, Business Development Director at Novozymes Biopharma. “Novozymes has enjoyed a successful relationship with Upperton over the past 10 years and its expertise and experience in the conjugation of proteins, combined with our experience of protein engineering and production, will help customers to design drugs with tailored serum half-life and fewer side-effects. This will result in improved dosing regimes for the patient and a reduction in overall costs for the healthcare provider.”
By manipulating the interaction of albumin with its receptor, the neonatal Fc receptor (FcRn), Novozymes can produce modified albumins that bind with greater or lesser affinities, meaning a flexible half-life. Increasing the serum half-life of a drug may reduce the frequency of injections a patient receives or even reduce the amount of drug delivered, thereby significantly reducing toxic side-effects and increasing patient acceptance.
Upperton has demonstrated that proteins, peptides and small molecule APIs can be covalently attached to recombinant human albumin using a range of chemistries. Additionally, once drugs have been linked to the recombinant human albumin carrier, they exhibit dramatically improved pharmacokinetic and pharmacodynamic properties. Combining Novozymes' unique IP and know-how around the albumin molecules themselves with Upperton’s rP-conjugate™ albumin conjugation chemistry knowledge, enables the companies to work closely with customers to design and implement the best chemical linking approach for their molecule. As a result, Novozymes can provide partners with a unique service from initial product concept through to in vivo testing for developing novel drugs.
Richard Johnson, founder and CEO of Upperton Limited, comments “By combining Novozymes’ and Upperton’s unmatched expertise in our respective fields, we have developed a solution that solves industry challenges by enabling a tunable half-life that offers control and flexibility and has the potential to improve overall treatment efficacy.”
To learn more about Novozymes’ Recombumin Flex technology, please visit www.biopharma.novozymes.com.
To find out more about Upperton Limited, please visit www.upperton.com.
NOTTINGHAM, UK – December 8, 2011 – Novozymes Biopharma, part of Novozymes A/S, a world leader in bioinnovation, has announced that it has expanded its partnership with Nottingham-based research and development company, Upperton Limited, to offer customers a new albumin conjugation solution. By linking drugs to Novozymes’ new Recombumin® Flex recombinant human albumin (rAlbumin), using conjugation, their pharmacokinetic and pharmacodynamic properties can be dramatically enhanced. As a result, manufacturers can benefit from the ability to tailor and control the half-life of drugs to fit patients’ medical needs.
“Novozymes is delighted to unveil Recombumin Flex along with our new conjugation solution in partnership with Upperton Limited,” says Dave Mead, Business Development Director at Novozymes Biopharma. “Novozymes has enjoyed a successful relationship with Upperton over the past 10 years and its expertise and experience in the conjugation of proteins, combined with our experience of protein engineering and production, will help customers to design drugs with tailored serum half-life and fewer side-effects. This will result in improved dosing regimes for the patient and a reduction in overall costs for the healthcare provider.”
By manipulating the interaction of albumin with its receptor, the neonatal Fc receptor (FcRn), Novozymes can produce modified albumins that bind with greater or lesser affinities, meaning a flexible half-life. Increasing the serum half-life of a drug may reduce the frequency of injections a patient receives or even reduce the amount of drug delivered, thereby significantly reducing toxic side-effects and increasing patient acceptance.
Upperton has demonstrated that proteins, peptides and small molecule APIs can be covalently attached to recombinant human albumin using a range of chemistries. Additionally, once drugs have been linked to the recombinant human albumin carrier, they exhibit dramatically improved pharmacokinetic and pharmacodynamic properties. Combining Novozymes' unique IP and know-how around the albumin molecules themselves with Upperton’s rP-conjugate™ albumin conjugation chemistry knowledge, enables the companies to work closely with customers to design and implement the best chemical linking approach for their molecule. As a result, Novozymes can provide partners with a unique service from initial product concept through to in vivo testing for developing novel drugs.
Richard Johnson, founder and CEO of Upperton Limited, comments “By combining Novozymes’ and Upperton’s unmatched expertise in our respective fields, we have developed a solution that solves industry challenges by enabling a tunable half-life that offers control and flexibility and has the potential to improve overall treatment efficacy.”
To learn more about Novozymes’ Recombumin Flex technology, please visit www.biopharma.novozymes.com.
To find out more about Upperton Limited, please visit www.upperton.com.
SmartKem Expands International Presence with Appointment of Japanese Representative
(9 December, 2011) – SmartKem Limited, the developer of high performance, printable organic semiconductor materials for flexible electronics, today announced the appointment of a Japanese representative, Dr. Yutaka Hirai of Business Link Japan. This partnership, combining SmartKem’s niche scientific expertise and the consultation services of Dr. Hirai, will support SmartKem’s growth in the TFT and electronics display market. The expansion will enable the company to target the complete supply chain in Japan, from chemical suppliers to printing specialists and electronics manufacturers. With a strong heritage in the development of organic semiconductor technology for TFT display applications, SmartKem will deliver customised ink formulations that are designed to enable the manufacture of lightweight, ultra-thin and rugged flat panel displays as used in smartphones, laptops, tablet PCs and TV screens.
Based in Tokyo, Japan, Dr. Hirai brings to the role extensive high level technology experience, having worked for large organizations such as Canon Inc. at senior management and Director level. Dr. Hirai has specialist expertise in semiconductor materials and devices for applications such as displays, sensors, solar cells and fuel cells. Dr. Hirai will be responsible for ensuring that SmartKem’s world class organic semiconductor materials are directed at leading Japanese organisations who are involved in the development and manufacture of flexible, lightweight and large-area printed electronics. Priority will be given to market-driven applications such as EPD, OLED and HD LCD display industries. Asia is the home of electronic device manufacturing and provides an exciting market potential for SmartKem’s technology. The appointment of a highly respected representative in Japan marks the starting point of SmartKem’s Asian strategy.
“I am very excited to have the opportunity to represent SmartKem in Japan. The future of lightweight and flexible electronics will be driven by pioneering advances in material technology that will enable limitless applications comments Dr. Hirai. SmartKem is leading the development of these materials and it is with great pride that I will represent the company in the Japanese market with ground-breaking organic semiconductor solutions.”
"The global market for ultra-thin, lightweight printable electronics is growing rapidly and is estimated to reach $45 billion by 2016. Being a fast evolving industrial market, Japan is expected to play a key role in new developments, offering exceptional growth opportunities for forward-looking companies such as SmartKem adds Steve Kelly, CEO of SmartKem. Dr. Hirai is highly respected in the electronics industry and has impressive credentials within our target market sectors. We are confident that he will exceed our expectations and help us achieve our goal of becoming the leading independent provider of organic semiconductor solutions for TFT displays.”
SmartKem was advised by Peter Bacon of Electronics Link Asia on this project.
For more information on SmartKem and its innovative materials, please call 01745 535190, email enquiries@smartkem.com or visit www.smartkem.com
-ENDS-
About SmartKem
SmartKem is a high tech enterprise developing an exciting new technology platform focusing on high performance/high value organic semiconductor materials that can be ‘printed’ to form electronic circuits onto lightweight, rugged and low cost polymer films. Based in the world class Optic Technium centre, North Wales, SmartKem’s main objective is to respond to the demand for low cost, low weight, low energy, rugged electronics. The SmartKem team has proven expertise and experience in the fields of organic semiconductors, specialist ink-technology and printable transistors and was a recent winner of the inaugural Oxford Venturefest gold award for ‘British Technology Innovation of the Year’.
Based in Tokyo, Japan, Dr. Hirai brings to the role extensive high level technology experience, having worked for large organizations such as Canon Inc. at senior management and Director level. Dr. Hirai has specialist expertise in semiconductor materials and devices for applications such as displays, sensors, solar cells and fuel cells. Dr. Hirai will be responsible for ensuring that SmartKem’s world class organic semiconductor materials are directed at leading Japanese organisations who are involved in the development and manufacture of flexible, lightweight and large-area printed electronics. Priority will be given to market-driven applications such as EPD, OLED and HD LCD display industries. Asia is the home of electronic device manufacturing and provides an exciting market potential for SmartKem’s technology. The appointment of a highly respected representative in Japan marks the starting point of SmartKem’s Asian strategy.
“I am very excited to have the opportunity to represent SmartKem in Japan. The future of lightweight and flexible electronics will be driven by pioneering advances in material technology that will enable limitless applications comments Dr. Hirai. SmartKem is leading the development of these materials and it is with great pride that I will represent the company in the Japanese market with ground-breaking organic semiconductor solutions.”
"The global market for ultra-thin, lightweight printable electronics is growing rapidly and is estimated to reach $45 billion by 2016. Being a fast evolving industrial market, Japan is expected to play a key role in new developments, offering exceptional growth opportunities for forward-looking companies such as SmartKem adds Steve Kelly, CEO of SmartKem. Dr. Hirai is highly respected in the electronics industry and has impressive credentials within our target market sectors. We are confident that he will exceed our expectations and help us achieve our goal of becoming the leading independent provider of organic semiconductor solutions for TFT displays.”
SmartKem was advised by Peter Bacon of Electronics Link Asia on this project.
For more information on SmartKem and its innovative materials, please call 01745 535190, email enquiries@smartkem.com or visit www.smartkem.com
-ENDS-
About SmartKem
SmartKem is a high tech enterprise developing an exciting new technology platform focusing on high performance/high value organic semiconductor materials that can be ‘printed’ to form electronic circuits onto lightweight, rugged and low cost polymer films. Based in the world class Optic Technium centre, North Wales, SmartKem’s main objective is to respond to the demand for low cost, low weight, low energy, rugged electronics. The SmartKem team has proven expertise and experience in the fields of organic semiconductors, specialist ink-technology and printable transistors and was a recent winner of the inaugural Oxford Venturefest gold award for ‘British Technology Innovation of the Year’.
Wednesday 30 November 2011
Thermo Fisher Scientific Fluorospectrometer Implemented by the University of California to improve the accuracy and efficiency of GFR Measurements in mice
WILMINGTON, Del. (November 30 2011) – Thermo Fisher Scientific Inc., the world leader in serving science, today announced that the University of California (UC), San Diego, Division of Nephrology/Hypertension has implemented a Thermo Scientific NanoDrop 3300 Fluorospectrometer as the fluorescent detection system for mouse glomerular filtration rate (GFR) determination. The Thermo Scientific NanoDrop 3300 Fluorospectrometer offers a reliable micro-volume fluorescent platform for repeated determination of GFR in conscious mice to assess their renal function without surgical procedures. The instrument allows scientists to perform these measurements simply, quickly and cost-effectively, making the instrument a valuable tool for GFR research applications. A new application note entitled ‘Measuring Mouse GFR by Fluorescein isothiocyanate (FITC)-Inulin using the Thermo Scientific NanoDrop 3300 Fluorospectrometer’, is available for download at http://www.nanodrop.com/3300apps.html
UC San Diego’s Division of Nephrology/Hypertension considers GFR measurement to be the most reliable method in renal function assessment and as such the technique is utilized by the team to determine GFR under physiological and pathophysiological conditions in mice. In the past, the division determined GFR by measuring radioactively labeled inulin in blood plasma and urine in anesthetized animals. However, anesthesia has multiple effects on the physiology of the mammalian body and repetitive measurements are difficult to perform. As this limitation significantly impacted the study designs, the division sought an alternative method.
Jouez la carte de l’écologie avec le cadeau idéal pour les amateurs de jardinage!
(Gloucester, Massachusetts) 29 Novembre 2011- Comblez les passionnés de jardinage avec la pompe à eau solaire RainPerfect de Rule Innovation, une marque Xylem. Ne vous cassez pas la tête pour trouver un cadeau de Noël : le système RainPerfect est le cadeau de jardinage idéal pour ceux qui ont déjà tout !
La pompe RainPerfect de Rule Innovation permet de recycler les ressources des réservoirs à eau de pluie puis de générer une pression suffisante pour alimenter la plupart des pistolets d’arrosage ou des asperseurs. D’une grande efficacité, la pompe RainPerfect fonctionne grâce à un panneau solaire de 3,5 watts, ce qui en fait le cadeau idéal pour tous les jardiniers soucieux de l’environnement. La pompe RainPerfect est une méthode efficace et simple pour placer son jardin sous le signe du développement durable. De plus, alors que le coût de l’énergie ne cesse d’augmenter, l’alimentation solaire de la pompe RainPerfect présente des avantages écologiques et économiques indéniables.
Une période de fêtes réussie avec la pompe à eau sans fil AquaCharge de Rule Innovation
Gloucester, Massachusetts, 29 Novembre 2011 – Les amateurs de navigation de plaisance et de jardinage vont adorer l'AquaCharge de Rule Innovation (une marque Xylem). Plus besoin d’écumer les magasins à la recherche du cadeau parfait : l’AquaCharge est le cadeau idéal pour les fêtes de fin d’année !
Cette innovante pompe à eau sans fil peut être utilisée pour de nombreuses applications classiques telles que le drainage des bassins et des pièces d'eau du jardin, et des aquariums. En dehors du jardin, cette pompe est une solution efficace pour évacuer l'eau des kayaks, canoës et voiliers.
De dimensions modestes (17,8 x 8,3 x 14 cm) et légère (1,6 kg), la pompe portable et rechargeable de Rule Innovation constitue un objet domestique maniable et facile à utiliser. La pompe peut se raccorder à n'importe quel tuyau de jardin standard pour être facilement utilisée dans des jardins de toute taille. Sa capacité de pompage est de 754,5 litres par charge.
Friday 25 November 2011
Neuartige kabellose Wasserpumpe AquaCharge von Rule Innovation– eine außergewöhnliche Geschenkidee zu Weihnachten
Gloucester, MA, USA (23 November 2011) – Darauf haben Boots- und Gartenfreunde schon lange gewartet: die kabellose Wasserpumpe AquaCharge von Rule Innovation, einer Marke von Xylem. Suchen Sie nicht länger nach dem idealen Geschenk: Die AquaCharge ist genau das Richtige für Weihnachten! Die innovative, kabellose Wasserpumpe eignet sich bestens zum Abpumpen von Gartenteichen, Wasserbecken, Aquarien usw. Außerdem lässt sich die AquaCharge sehr effizient als Lenzpumpe für Kajaks, Kanus und Segelboote nutzen.
Die tragbare, akkubetriebene AquaCharge von Rule Innovation ist dank ihrer kompakten Abmessungen (ca. 18 x 8 x 14 cm) und des geringen Gewichts (ca. 1,6 kg) sehr leicht und praktisch in der Handhabung. Sie lässt sich an alle Standardgartenschläuche anschließen und in Gärten jeder Größe einsetzen.
Auf ein grünes neues Jahr – mit dem idealen Geschenk für Hobbygärtner!
Gloucester, MA, USA (23 November 2011) – Überraschen Sie die Hobbygärtner in Ihrem Freundeskreis mit der solarbetriebenen Wasserpumpe RainPerfect von Rule Innovation, einer Marke von Xylem. Suchen Sie nicht länger nach dem idealen Geschenk: RainPerfect ist genau das Richtige für Gartenfreunde, die schon alles haben!
Die Wasserpumpe RainPerfect von Rule Innovation erzeugt genügend Druck für einen Gartenschlauch oder Rasensprenger und ermöglicht so die komfortable Bewässerung des Gartens mit Wasser aus der Regentonne. Betrieben wird die RainPerfect mit einem 3,5-Watt-Solarpaneel und präsentiert sich damit als umweltfreundliches Geschenk für alle, die im neuen Jahr ökologische Vorsätze verwirklichen wollen. Die RainPerfect ist der einfachste Weg zu nachhaltiger und dabei höchst effektiver Gartenpflege. Und angesichts der steigenden Energiekosten ist die solarbetriebene RainPerfect nicht nur umweltfreundlich, sondern auch wirtschaftlich attraktiv.
Die Wasserpumpe RainPerfect von Rule Innovation erzeugt genügend Druck für einen Gartenschlauch oder Rasensprenger und ermöglicht so die komfortable Bewässerung des Gartens mit Wasser aus der Regentonne. Betrieben wird die RainPerfect mit einem 3,5-Watt-Solarpaneel und präsentiert sich damit als umweltfreundliches Geschenk für alle, die im neuen Jahr ökologische Vorsätze verwirklichen wollen. Die RainPerfect ist der einfachste Weg zu nachhaltiger und dabei höchst effektiver Gartenpflege. Und angesichts der steigenden Energiekosten ist die solarbetriebene RainPerfect nicht nur umweltfreundlich, sondern auch wirtschaftlich attraktiv.
Wednesday 23 November 2011
Analytical Technology Continues Water Monitoring Success by Securing Prestigious Framework Agreement with Wessex Water
Analytical Technology Continues Water Monitoring Success by Securing Prestigious Framework Agreement with Wessex Water
Manchester, UK (November 22, 2011) Specialist electrochemical sensor manufacturer Analytical Technology Inc. today announces that it has been awarded a framework agreement to supply dissolved ammonia monitoring systems to Wessex Water.
Following a detailed decision-making process in which Wessex Water evaluated a range of monitors against stringent criteria, Analytical Technology was awarded an AMP 5 framework agreement for its Q45N dissolved ammonia monitor.
Wessex Water is a regional water and sewage treatment business serving an area of the south west of England, covering 10,000 square kilometres including Dorset, Somerset, Bristol, most of Wiltshire and parts of Gloucestershire and Hampshire. The new agreement reaffirms Analytical Technology’s position as a leading supplier of water monitoring instrumentation to the majority of the UK’s largest utility companies, including Thames Water, Yorkshire Water, South West Water, United Utilities, Anglian Water and Severn Trent.
Analytical Technology’s Q45N dissolved ammonia monitor provides a new approach to on-line ammonia monitoring. The system uses reaction chemistry that converts ammonia in solution to a stable monochloramine compound that is equivalent in concentration to the original ammonia level. The chloramine concentration is then measured with a unique amperometric sensor that responds linearly to chloramines, while eliminating interference from excess free chlorine in solution. The Q45N system provides the measurement stability needed to avoid complicated automatic calibration systems and provides excellent repeatability over long periods.
For more information on Analytical Technology’s dissolved ammonia monitoring systems, please call +44(0)1457 873 318, e-mail sales@atiuk.com or visit www.analyticaltechnology.com.
Manchester, UK (November 22, 2011) Specialist electrochemical sensor manufacturer Analytical Technology Inc. today announces that it has been awarded a framework agreement to supply dissolved ammonia monitoring systems to Wessex Water.
Following a detailed decision-making process in which Wessex Water evaluated a range of monitors against stringent criteria, Analytical Technology was awarded an AMP 5 framework agreement for its Q45N dissolved ammonia monitor.
Wessex Water is a regional water and sewage treatment business serving an area of the south west of England, covering 10,000 square kilometres including Dorset, Somerset, Bristol, most of Wiltshire and parts of Gloucestershire and Hampshire. The new agreement reaffirms Analytical Technology’s position as a leading supplier of water monitoring instrumentation to the majority of the UK’s largest utility companies, including Thames Water, Yorkshire Water, South West Water, United Utilities, Anglian Water and Severn Trent.
Analytical Technology’s Q45N dissolved ammonia monitor provides a new approach to on-line ammonia monitoring. The system uses reaction chemistry that converts ammonia in solution to a stable monochloramine compound that is equivalent in concentration to the original ammonia level. The chloramine concentration is then measured with a unique amperometric sensor that responds linearly to chloramines, while eliminating interference from excess free chlorine in solution. The Q45N system provides the measurement stability needed to avoid complicated automatic calibration systems and provides excellent repeatability over long periods.
For more information on Analytical Technology’s dissolved ammonia monitoring systems, please call +44(0)1457 873 318, e-mail sales@atiuk.com or visit www.analyticaltechnology.com.
Thermo Fisher Scientific Names Winner of 2012 Winter Conference Award in Plasma Spectrochemistry
SAN JOSE, Calif. (November 17, 2011) – Thermo Fisher Scientific Inc., the world leader in serving science, today announced the winner of the 2012 Winter Conference Award in Plasma Spectrochemistry, Dr. J. Sabine Becker, head of Trace and UltraTrace Analysis, Central Division of Analytical Chemistry at the Research Center Juelich, Germany. The award, which honors scientists who have made the most noteworthy contributions to the field of plasma spectrochemistry, is sponsored by Thermo Fisher. Thermo Fisher will present the award and a check for $5,000 to Dr. Becker during the 2012 Winter Conference on Plasma Spectrochemistry to be held in Tucson, Ariz. January 9–14, 2012.
Dr. Becker’s distinguished career in analytical chemistry has focused on long-lived radionuclides, ultratrace and high-purity materials analysis, isotope ratio measurements, and micro and nanolocal elemental and trace analyses. Recently she established BrainMet, an Analytical Center of Excellence at the Research Centre Juelich for brain research imaging. Based on laser ablation inductively coupled plasma mass spectrometry (LA-ICP-MS), BrainMet has introduced novel imaging techniques for metals, metalloids and non-metals in biological tissues. The approach provides quantitative mapping of essential and toxic elements in thin sections of diseased and healthy medical and biological tissue sections.
Wednesday 16 November 2011
Novozymes Biopharma supplies R-Tech Ueno with Albucult® for use in unique dry eye therapy
New treatment will be the first of its kind to utilize the benefits of Novozymes’ recombinant human albumin
NOTTINGHAM, UK – November 15, 2011 – Novozymes Biopharma, part of Novozymes A/S world leader in bioinnovation, has announced that its recombinant human albumin, Albucult®, has been selected by R-Tech Ueno for use in a unique treatment for dry eye syndrome. R-Tech Ueno is a global pharmaceutical company specializing in the fields of ophthalmology and dermatology. The Japan-based company will utilize Albucult as a key component in its new therapy which will be the first of its kind developed for the treatment of severe and moderate dry eye conditions. Albucult is manufactured by Novozymes’ long-term technology partner Kaketsuken based in Kumamoto, Japan and marketed by Novozymes world-wide.
Dr Yukihiko Mashima, President of R-Tech Ueno, comments: “Novozymes’ and Kaketsuken’s commitment to supplying products that enhance the safety profile and quality of their partners’ medicines makes them the ideal collaborators for us to work with. Novozymes has a wealth of experience of biomaterials and sets the benchmark for recombinant human albumin.”
Prevalence of dry eye syndrome continues to increase, with the condition having the highest rate of diagnosis of all ophthalmic disorders. As an active ingredient, Albucult® confers a range of unique advantages to the development of R-Tech Ueno’s new therapy including an exceptional purity profile and excellent batch-to-batch consistency, which is not possible with animal-derived ingredients.
Dermot Pearson, Marketing Director at Novozymes Biopharma, comments: “Novozymes is delighted that R-Tech Ueno has selected Albucult for use in the development of this innovative new treatment. The partnership demonstrates our commitment to supplying customers with quality biomaterials that reduce operational and regulatory complexity and minimize manufacturing risk.”
The use of Albucult in R-Tech Ueno’s therapy and other drugs can help to optimize pathways through regulatory approval procedures and improve time–to-market. Albucult also delivers unprecedented performance benefits to protein therapeutics and medical devices while ensuring security of supply and consistent quality. This can drive product development efficiency for customers looking for a compliant albumin alternative.
For further information on Novozymes Biopharma’s Albucult, please visit www.biopharma.novozymes.com
###
About Novozymes
Novozymes is the world leader in bioinnovation. Together with customers across a broad array of industries, we create tomorrow’s industrial biosolutions, improving our customers' business and the use of our planet's resources.
With over 700 products used in 130 countries, Novozymes’ bioinnovations improve industrial performance and safeguard the world’s resources by offering superior and sustainable solutions for tomorrow’s ever-changing marketplace. Read more at www.novozymes.com.
Contact:
Novozymes Biopharma:
Sally Vernon, Customer Communications Manager
SYKE@novozymes.com
Tel. +44 115 955 3355
NOTTINGHAM, UK – November 15, 2011 – Novozymes Biopharma, part of Novozymes A/S world leader in bioinnovation, has announced that its recombinant human albumin, Albucult®, has been selected by R-Tech Ueno for use in a unique treatment for dry eye syndrome. R-Tech Ueno is a global pharmaceutical company specializing in the fields of ophthalmology and dermatology. The Japan-based company will utilize Albucult as a key component in its new therapy which will be the first of its kind developed for the treatment of severe and moderate dry eye conditions. Albucult is manufactured by Novozymes’ long-term technology partner Kaketsuken based in Kumamoto, Japan and marketed by Novozymes world-wide.
Dr Yukihiko Mashima, President of R-Tech Ueno, comments: “Novozymes’ and Kaketsuken’s commitment to supplying products that enhance the safety profile and quality of their partners’ medicines makes them the ideal collaborators for us to work with. Novozymes has a wealth of experience of biomaterials and sets the benchmark for recombinant human albumin.”
Prevalence of dry eye syndrome continues to increase, with the condition having the highest rate of diagnosis of all ophthalmic disorders. As an active ingredient, Albucult® confers a range of unique advantages to the development of R-Tech Ueno’s new therapy including an exceptional purity profile and excellent batch-to-batch consistency, which is not possible with animal-derived ingredients.
Dermot Pearson, Marketing Director at Novozymes Biopharma, comments: “Novozymes is delighted that R-Tech Ueno has selected Albucult for use in the development of this innovative new treatment. The partnership demonstrates our commitment to supplying customers with quality biomaterials that reduce operational and regulatory complexity and minimize manufacturing risk.”
The use of Albucult in R-Tech Ueno’s therapy and other drugs can help to optimize pathways through regulatory approval procedures and improve time–to-market. Albucult also delivers unprecedented performance benefits to protein therapeutics and medical devices while ensuring security of supply and consistent quality. This can drive product development efficiency for customers looking for a compliant albumin alternative.
For further information on Novozymes Biopharma’s Albucult, please visit www.biopharma.novozymes.com
###
About Novozymes
Novozymes is the world leader in bioinnovation. Together with customers across a broad array of industries, we create tomorrow’s industrial biosolutions, improving our customers' business and the use of our planet's resources.
With over 700 products used in 130 countries, Novozymes’ bioinnovations improve industrial performance and safeguard the world’s resources by offering superior and sustainable solutions for tomorrow’s ever-changing marketplace. Read more at www.novozymes.com.
Contact:
Novozymes Biopharma:
Sally Vernon, Customer Communications Manager
SYKE@novozymes.com
Tel. +44 115 955 3355
Tuesday 15 November 2011
Thermo Fisher Scientific Announces New Method for Low Level Detection of Volatile Nitrosamines in Tobacco
SAN JOSE, Calif., (November 14, 2011) – Thermo Fisher Scientific Inc., the world leader in serving science, today announced a new comprehensive method that uses triple quadrupole GC-MS/MS to achieve lower levels of detection of volatile nitrosamines (VNA) in tobacco. The new method allows environmental laboratories, tobacco companies and government agencies to efficiently separate VNAs while lowering detection limits, increasing specificity and enabling the analysis of many other contaminants in tobacco, including pesticides. The new method is detailed in an application note entitled “Lower Detection Limits of Volatile Nitrosamines in Tobacco by Triple Quadrupole GC-MS/MS,” available to download at www.thermoscientific.com/vna.
Volatile nitrosamines are a class of compounds that can form in tobacco smoke, as well as during the curing and processing of tobacco. These compounds have been proven to have adverse effects on human health; and two of the VNAs found in tobacco, N-nitrosodiethylamine (NDEA) and N-nitrosodimethylamine (NDMA), are classed as known human carcinogens by regulatory authorities. As a result, these compounds must be thoroughly monitored in order to safeguard human health and comply with increasingly stringent regulations.
The new Thermo Fisher method is a powerful alternative to other traditionally used techniques. By coupling a gas chromatograph to a triple quadrupole mass spectrometer, the new method makes detection limits of 1ng/mL achievable, enabling users to satisfy the increasingly lower detection limits required by governments and regulatory bodies. The method also increases contaminant specificity within a classification and allows many other organic contaminants and chemicals in tobacco to be analyzed simultaneously, including pesticides.
The new method includes GC-MS/MS analysis on the Thermo Scientific TSQ Quantum XLS triple quadrupole GC-MS/MS system using timed selected reaction monitoring (t-SRM). This unique feature enables easy method set-up and allows users to run samples while the instrument automatically determines the optimal time for SRM parameters.
For more information on the new Thermo Fisher GC/MS-MS method for the detection of VNAs in tobacco or to obtain a copy of the application note, please call +1 866-463-6522, e-mail analyze@thermofisher.com or visit www.thermoscientific.com/gc.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science. Our mission is to enable our customers to make the world healthier, cleaner and safer. With revenues of nearly $11 billion, we have approximately 37,000 employees and serve customers within pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as in environmental and process control industries. We create value for our key stakeholders through two premier brands, Thermo Scientific and Fisher Scientific, which offer a unique combination of continuous technology development and the most convenient purchasing options. Our products and services help accelerate the pace of scientific discovery, and solve analytical challenges ranging from complex research to routine testing to field applications. Visit www.thermofisher.com
Volatile nitrosamines are a class of compounds that can form in tobacco smoke, as well as during the curing and processing of tobacco. These compounds have been proven to have adverse effects on human health; and two of the VNAs found in tobacco, N-nitrosodiethylamine (NDEA) and N-nitrosodimethylamine (NDMA), are classed as known human carcinogens by regulatory authorities. As a result, these compounds must be thoroughly monitored in order to safeguard human health and comply with increasingly stringent regulations.
The new Thermo Fisher method is a powerful alternative to other traditionally used techniques. By coupling a gas chromatograph to a triple quadrupole mass spectrometer, the new method makes detection limits of 1ng/mL achievable, enabling users to satisfy the increasingly lower detection limits required by governments and regulatory bodies. The method also increases contaminant specificity within a classification and allows many other organic contaminants and chemicals in tobacco to be analyzed simultaneously, including pesticides.
The new method includes GC-MS/MS analysis on the Thermo Scientific TSQ Quantum XLS triple quadrupole GC-MS/MS system using timed selected reaction monitoring (t-SRM). This unique feature enables easy method set-up and allows users to run samples while the instrument automatically determines the optimal time for SRM parameters.
For more information on the new Thermo Fisher GC/MS-MS method for the detection of VNAs in tobacco or to obtain a copy of the application note, please call +1 866-463-6522, e-mail analyze@thermofisher.com or visit www.thermoscientific.com/gc.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science. Our mission is to enable our customers to make the world healthier, cleaner and safer. With revenues of nearly $11 billion, we have approximately 37,000 employees and serve customers within pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as in environmental and process control industries. We create value for our key stakeholders through two premier brands, Thermo Scientific and Fisher Scientific, which offer a unique combination of continuous technology development and the most convenient purchasing options. Our products and services help accelerate the pace of scientific discovery, and solve analytical challenges ranging from complex research to routine testing to field applications. Visit www.thermofisher.com
Synergy Health Announces Contract Extension With Homerton University Hospital
Swindon, UK (11 November 2011) – Synergy Health plc, the leading provider of specialist outsourced services to healthcare providers, is pleased to announce that Homerton University Hospital NHS Foundation Trust has extended its contract with the company, entering into a new sterile services agreement (for decontamination of surgical instruments) which also includes the supply of over 10,000 theatre consumables (single use bowl sets). Synergy Health delivers a range of specialist outsourced services to healthcare providers across Europe and China, aimed at supporting customers to improve the quality and efficiency of their activities, reducing risks to patients and clients. The contract is a continuation of the long standing relationship between the organizations.
The contract was awarded following a competitive tender process, with Synergy Health offering a number of innovative solutions. The company’s CEO, UK and Ireland, Adrian Coward said: “Synergy Health is a trusted and proven partner to the NHS, continually striving for mutual success based on trust, innovation and accountability. It is deeply committed to delivering the highest quality in everything it does, going the extra mile to make a difference; solve problems and reduce risk. For Homerton we incorporated single use and reusable theatre consumables into the agreement, offering significant price benefits and added value, with the potential of increasing our supply of medical products.”
Synergy Health has been running the Trust’s sterile services department for a number of years, processing around 1 million items per year. The company is fully engaged with economic pressures facing the NHS and its services offer significant economies of scale and efficiency savings to clients, backed by an exemplary track record in regulatory compliance. The company believes that improved business outcomes can be achieved by working collaboratively.
Synergy Health works with leading instrument suppliers on improving design and reducing tray defects and enjoys very low defect rates. A testament to the established relationship between Synergy Health and its customers are the high quality standards hospitals are continuing to experience, benefiting from exceptionally low defect and rejection rates from both sides of the partnership.
Adrian Coward continued: “This continued collaboration demonstrates the success of long-lasting relationships and confirms that public and private sectors can work together to provide excellent integrated services to patients. The innovative solutions offer value for money, quality enhancements and improved services, from both in-house suppliers and third party distributors.”
To learn more Synergy Health’s services, please visit www.synergyhealthplc.com, contact decontamination@synergyhealthplc.com or alternatively call 01582 501234
Notes to editors:
About Synergy Health
Synergy Health is the largest provider of outsourced hospital sterilisation services in Europe with 19 facilities across the UK and further facilities in Belgium, Netherlands and China. It safely sterilises around 60 million surgical instruments each year from NHS acute and primary Trusts and the independent sector throughout the country.
Synergy’s services offer significant economies of scale and efficiency savings to the NHS, is fully engaged with the reforms in healthcare and is committed to supporting the NHS in reducing its cost burden while striving for the highest quality of care and best outcomes for patients.
For further press information please contact: Sarah Evans, The Scott Partnership, 1 Whiteside, Station Road, Holmes Chapel, Cheshire. CW4 8AA United Kingdom Tel: + 44 1477 539539 Fax: +44 1477 539540 mail to: synergy@scottpr.com
The contract was awarded following a competitive tender process, with Synergy Health offering a number of innovative solutions. The company’s CEO, UK and Ireland, Adrian Coward said: “Synergy Health is a trusted and proven partner to the NHS, continually striving for mutual success based on trust, innovation and accountability. It is deeply committed to delivering the highest quality in everything it does, going the extra mile to make a difference; solve problems and reduce risk. For Homerton we incorporated single use and reusable theatre consumables into the agreement, offering significant price benefits and added value, with the potential of increasing our supply of medical products.”
Synergy Health has been running the Trust’s sterile services department for a number of years, processing around 1 million items per year. The company is fully engaged with economic pressures facing the NHS and its services offer significant economies of scale and efficiency savings to clients, backed by an exemplary track record in regulatory compliance. The company believes that improved business outcomes can be achieved by working collaboratively.
Synergy Health works with leading instrument suppliers on improving design and reducing tray defects and enjoys very low defect rates. A testament to the established relationship between Synergy Health and its customers are the high quality standards hospitals are continuing to experience, benefiting from exceptionally low defect and rejection rates from both sides of the partnership.
Adrian Coward continued: “This continued collaboration demonstrates the success of long-lasting relationships and confirms that public and private sectors can work together to provide excellent integrated services to patients. The innovative solutions offer value for money, quality enhancements and improved services, from both in-house suppliers and third party distributors.”
To learn more Synergy Health’s services, please visit www.synergyhealthplc.com, contact decontamination@synergyhealthplc.com or alternatively call 01582 501234
Notes to editors:
About Synergy Health
Synergy Health is the largest provider of outsourced hospital sterilisation services in Europe with 19 facilities across the UK and further facilities in Belgium, Netherlands and China. It safely sterilises around 60 million surgical instruments each year from NHS acute and primary Trusts and the independent sector throughout the country.
Synergy’s services offer significant economies of scale and efficiency savings to the NHS, is fully engaged with the reforms in healthcare and is committed to supporting the NHS in reducing its cost burden while striving for the highest quality of care and best outcomes for patients.
For further press information please contact: Sarah Evans, The Scott Partnership, 1 Whiteside, Station Road, Holmes Chapel, Cheshire. CW4 8AA United Kingdom Tel: + 44 1477 539539 Fax: +44 1477 539540 mail to: synergy@scottpr.com
Friday 11 November 2011
Thermo Fisher Scientific Launches Technical Library on LC-MS Solutions for
LC-MS Solutions Simplify Sample Preparation Time and Maximize Mass Spec Throughput
SAN JOSE, Calif. (November 11, 2011) – Thermo Fisher Scientific Inc., the world leader in serving science, today announced the availability of a new technical library of liquid chromatography-mass spectrometry (LC-MS) solutions for endocrine drug analysis in clinical research, including methods showcasing the ability of automated sample preparation and multiplexing to reduce sample preparation time and maximize mass spectrometer throughput.
The regularly updated technical library, available at thermoscientific.com/lcmsendo, comprises detailed publications from Thermo Fisher’s dedicated global clinical research team, which develops faster and more analytically sensitive methods for endocrine drug analysis for its research clients. The new library is a comprehensive resource containing application notes, webinars, technical posters, case studies, videos and web resources for numerous applications.
“We designed the LC-MS technical library for endocrine drug analysis to help laboratory managers and technicians better understand the power of LC-MS technology for clinical research. We believe what they learn from this great resource will help maximize their sample throughput, improve turnaround time and reduce overall analysis cost, without compromising data quality for drug analysis,” said Ian Jardine, vice president of global R&D, Thermo Fisher.
The technical library includes the latest applications utilized for the analysis of endocrine drugs in clinical research, including:
- Immunoaffinity for research analysis of 1,25D
- Automated online sample preparation for time savings
- UHPLC for higher throughput
- Triple stage quadrupole for necessary LOQ and dynamic range
- High-resolution, accurate mass for difficult endogenous molecules
The online technical library, designed as a knowledge transfer tool, is available free of charge at thermoscientific.com/lcmsendo.
For Research Use Only. Not for use in diagnostic procedures.
For the latest information about Thermo Fisher Scientific solutions and the wide range of applications for endocrine drug analysis, please call +1 800 532 4752, e-mail analyze@thermofisher.com or visit www.thermoscientific.com/ms
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science. Our mission is to enable our customers to make the world healthier, cleaner and safer. With revenues of nearly $11 billion, we have approximately 37,000 employees and serve customers within pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as in environmental and process control industries. We create value for our key stakeholders through two premier brands, Thermo Scientific and Fisher Scientific, which offer a unique combination of continuous technology development and the most convenient purchasing options. Our products and services help accelerate the pace of scientific discovery, and solve analytical challenges ranging from complex research to routine testing to field applications. Visit www.thermofisher.com.
SAN JOSE, Calif. (November 11, 2011) – Thermo Fisher Scientific Inc., the world leader in serving science, today announced the availability of a new technical library of liquid chromatography-mass spectrometry (LC-MS) solutions for endocrine drug analysis in clinical research, including methods showcasing the ability of automated sample preparation and multiplexing to reduce sample preparation time and maximize mass spectrometer throughput.
The regularly updated technical library, available at thermoscientific.com/lcmsendo, comprises detailed publications from Thermo Fisher’s dedicated global clinical research team, which develops faster and more analytically sensitive methods for endocrine drug analysis for its research clients. The new library is a comprehensive resource containing application notes, webinars, technical posters, case studies, videos and web resources for numerous applications.
“We designed the LC-MS technical library for endocrine drug analysis to help laboratory managers and technicians better understand the power of LC-MS technology for clinical research. We believe what they learn from this great resource will help maximize their sample throughput, improve turnaround time and reduce overall analysis cost, without compromising data quality for drug analysis,” said Ian Jardine, vice president of global R&D, Thermo Fisher.
The technical library includes the latest applications utilized for the analysis of endocrine drugs in clinical research, including:
- Immunoaffinity for research analysis of 1,25D
- Automated online sample preparation for time savings
- UHPLC for higher throughput
- Triple stage quadrupole for necessary LOQ and dynamic range
- High-resolution, accurate mass for difficult endogenous molecules
The online technical library, designed as a knowledge transfer tool, is available free of charge at thermoscientific.com/lcmsendo.
For Research Use Only. Not for use in diagnostic procedures.
For the latest information about Thermo Fisher Scientific solutions and the wide range of applications for endocrine drug analysis, please call +1 800 532 4752, e-mail analyze@thermofisher.com or visit www.thermoscientific.com/ms
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science. Our mission is to enable our customers to make the world healthier, cleaner and safer. With revenues of nearly $11 billion, we have approximately 37,000 employees and serve customers within pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as in environmental and process control industries. We create value for our key stakeholders through two premier brands, Thermo Scientific and Fisher Scientific, which offer a unique combination of continuous technology development and the most convenient purchasing options. Our products and services help accelerate the pace of scientific discovery, and solve analytical challenges ranging from complex research to routine testing to field applications. Visit www.thermofisher.com.
Friday 4 November 2011
Exco InTouch Wins European Outsourcing Award for Second Year Running
Sawbridgeworth, UK – November 3, 2011- Exco InTouch, the leading provider of mobile patient communication solutions for the pharmaceutical and healthcare sectors, today announced another success in the prestigious European Outsourcing Awards, held in Frankfurt on 26 October 2011. In the second year running that the company has received the EOA award, Exco InTouch has been honoured with the accolade of ‘Best eBusiness/IT strategy’, which recognizes Exco InTouch’s collaboration with Pfizer. The study, which focused on new Research on Electronic Monitoring of OAB Treatment Experience (REMOTE), is the first Participatory Patient-Centred (PPC) clinical trial to be conducted. The Phase 4 trial was facilitated with the use of proven mobile eDiary technology from Exco InTouch, enabling patients to participate regardless of location, age or proximity to site.
In order to support the success of this patient-centred, field-based study, Pfizer required a mobile technology platform offering an ease-of-use interface that provided accessibility, particularly with older patients in mind. The familiar, light-weight and accessible nature of a regular cell phone loaded with intuitive software meant it was the natural choice for Pfizer. These ePRO diaries enabled Pfizer to interact directly with study participants in a personalised and cost-effective manner, sending reminders and motivational messages directly to the patient’s cell phone. As a result, this improved patient compliance and retention, increasing overall data accuracy. Patients were also able to manage their own trial remotely and report results directly to a trial investigator who kept close oversight of patient eligibility and safety.
Since its inception in 2005, the EOA awards has recognised new and significant developments in contract services and rewarded successful companies for their outstanding contribution to the industry throughout the year. Despite strong competition from multiple industry competitors, the EOA crowned Exco InTouch winners of the award for their contribution in facilitating the revolutionary study with its innovative eDiary technology and flexible, customised service. EOA judges were impressed by the potential of the cellphone-based ePRO technology to transform how patients access and participate in clinical trials and to accelerate clinical research while improving quality.
Tim Davis, CEO of Exco InTouch comments, “It is a great honour to win an award that recognizes the collaboration between Exco InTouch and Pfizer and the integral part Exco’s leading ePRO technology played in the revolutionary study. Together we have been able to meet our joint objective to focus on innovative advancements that will accelerate clinical research through enhanced data quality and improvement in the way that patients all over the world can access clinical trials.”
For further information on the Exco InTouch range of solutions, please call +44 1279 709 040 or +1 877 327 5777 or visit www.excointouch.com.
About Exco InTouch
Exco InTouch is the leading provider of regulatory compliant interactive mobile patient communication solutions for Patient Recruitment, Retention, Compliance, ePRO/eDiary and Late Phase studies. Using a combination of software and services, Exco InTouch solutions provide simple, quick and non-intrusive channels of communication that enables sponsors, CROs, sites and patient recruitment agencies, find the right patients; keep them in their studies; motivate them to maintain full compliance and facilitate the collection of quality patient data, thus ensuring a better overall patient experience.
These solutions are currently being used by hundreds of thousands of patients in over 70 countries, delivered in the local language and are fully compliant with HIPAA regulations, FDA CFR 21 Part 11 and all electronic communication privacy directives.
For more info on Exco InTouch visit http://www.excointouch.com
In order to support the success of this patient-centred, field-based study, Pfizer required a mobile technology platform offering an ease-of-use interface that provided accessibility, particularly with older patients in mind. The familiar, light-weight and accessible nature of a regular cell phone loaded with intuitive software meant it was the natural choice for Pfizer. These ePRO diaries enabled Pfizer to interact directly with study participants in a personalised and cost-effective manner, sending reminders and motivational messages directly to the patient’s cell phone. As a result, this improved patient compliance and retention, increasing overall data accuracy. Patients were also able to manage their own trial remotely and report results directly to a trial investigator who kept close oversight of patient eligibility and safety.
Since its inception in 2005, the EOA awards has recognised new and significant developments in contract services and rewarded successful companies for their outstanding contribution to the industry throughout the year. Despite strong competition from multiple industry competitors, the EOA crowned Exco InTouch winners of the award for their contribution in facilitating the revolutionary study with its innovative eDiary technology and flexible, customised service. EOA judges were impressed by the potential of the cellphone-based ePRO technology to transform how patients access and participate in clinical trials and to accelerate clinical research while improving quality.
Tim Davis, CEO of Exco InTouch comments, “It is a great honour to win an award that recognizes the collaboration between Exco InTouch and Pfizer and the integral part Exco’s leading ePRO technology played in the revolutionary study. Together we have been able to meet our joint objective to focus on innovative advancements that will accelerate clinical research through enhanced data quality and improvement in the way that patients all over the world can access clinical trials.”
For further information on the Exco InTouch range of solutions, please call +44 1279 709 040 or +1 877 327 5777 or visit www.excointouch.com.
About Exco InTouch
Exco InTouch is the leading provider of regulatory compliant interactive mobile patient communication solutions for Patient Recruitment, Retention, Compliance, ePRO/eDiary and Late Phase studies. Using a combination of software and services, Exco InTouch solutions provide simple, quick and non-intrusive channels of communication that enables sponsors, CROs, sites and patient recruitment agencies, find the right patients; keep them in their studies; motivate them to maintain full compliance and facilitate the collection of quality patient data, thus ensuring a better overall patient experience.
These solutions are currently being used by hundreds of thousands of patients in over 70 countries, delivered in the local language and are fully compliant with HIPAA regulations, FDA CFR 21 Part 11 and all electronic communication privacy directives.
For more info on Exco InTouch visit http://www.excointouch.com
Thermo Fisher Scientific Launches Technical Library of LC-MS Solutions for Quick and Easy Analysis of PPCPs and Pesticides in Water
LC-MS Solutions Reduce Sample Preparation Time While Maintaining Sensitivity and Selectivity
SAN JOSE, Calif. (November 4, 2011) – Thermo Fisher Scientific Inc., the world leader in serving science, today announced the availability of a new technical library of LC-MS solutions for water analysis, including application information on the detection of pharmaceuticals and personal care products (PPCPs) and pesticides.
The technical library, available at www.thermoscientific.com/lcmswater, is a comprehensive and regularly updated searchable resource containing application notes, webinars, technical posters, articles, case studies, videos and web resources for numerous applications, including the analysis of pesticides, PPCPs, herbicides, endocrine disruptors and perfluorinated compounds.
“We designed the LC-MS technical library to give our customers ready access to water and beverage analysis resources that can help them improve and simplify their laboratory operations,” said Dipankar Ghosh, Ph.D., strategic marketing manager for environmental and food safety solutions at Thermo Fisher Scientific. “Our innovative LC-MS systems support a wide variety of applications for water and beverage sampling, from targeted and non-targeted screening to quantitative and qualitative analyses. We are committed to making our customers’ analyses as easy as possible with solutions that address both existing and future environmental concerns.”
The Thermo Scientific EQuan MAX LC-MS solution is ideal for quick and easy detection of pesticides and PPCPs in surface and drinking water, reducing the time required for sample preparation while delivering the sensitivity and selectivity needed to identify analytes of interest. The EQuan MAX system is an automated, high-throughput LC-MS solution that offers improved productivity and simplified assay development. With its unique online sample enrichment technique, scientists can significantly reduce analysis time - from days to minutes. And its high injection volume (1-20mL) enables higher detection limits than conventional LC-MS/MS analysis.
The online technical library, designed as a knowledge transfer tool, provides customers with access to Thermo Fisher’s vast application expertise and a variety of technical applications for water analysis. The digital resource is available free at http://www.thermoscientific.com/lcmswater.
For the latest information about Thermo Fisher solutions and its wide range of applications for water and beverage analysis, please call +1 800 532 4752, e-mail analyze@thermofisher.com or visit www.thermoscientific.com/ms.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science. Our mission is to enable our customers to make the world healthier, cleaner and safer. With revenues of nearly $11 billion, we have approximately 37,000 employees and serve customers within pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as in environmental and process control industries. We create value for our key stakeholders through two premier brands, Thermo Scientific and Fisher Scientific, which offer a unique combination of continuous technology development and the most convenient purchasing options. Our products and services help accelerate the pace of scientific discovery, and solve analytical challenges ranging from complex research to routine testing to field applications. Visit www.thermofisher.com.
SAN JOSE, Calif. (November 4, 2011) – Thermo Fisher Scientific Inc., the world leader in serving science, today announced the availability of a new technical library of LC-MS solutions for water analysis, including application information on the detection of pharmaceuticals and personal care products (PPCPs) and pesticides.
The technical library, available at www.thermoscientific.com/lcmswater, is a comprehensive and regularly updated searchable resource containing application notes, webinars, technical posters, articles, case studies, videos and web resources for numerous applications, including the analysis of pesticides, PPCPs, herbicides, endocrine disruptors and perfluorinated compounds.
“We designed the LC-MS technical library to give our customers ready access to water and beverage analysis resources that can help them improve and simplify their laboratory operations,” said Dipankar Ghosh, Ph.D., strategic marketing manager for environmental and food safety solutions at Thermo Fisher Scientific. “Our innovative LC-MS systems support a wide variety of applications for water and beverage sampling, from targeted and non-targeted screening to quantitative and qualitative analyses. We are committed to making our customers’ analyses as easy as possible with solutions that address both existing and future environmental concerns.”
The Thermo Scientific EQuan MAX LC-MS solution is ideal for quick and easy detection of pesticides and PPCPs in surface and drinking water, reducing the time required for sample preparation while delivering the sensitivity and selectivity needed to identify analytes of interest. The EQuan MAX system is an automated, high-throughput LC-MS solution that offers improved productivity and simplified assay development. With its unique online sample enrichment technique, scientists can significantly reduce analysis time - from days to minutes. And its high injection volume (1-20mL) enables higher detection limits than conventional LC-MS/MS analysis.
The online technical library, designed as a knowledge transfer tool, provides customers with access to Thermo Fisher’s vast application expertise and a variety of technical applications for water analysis. The digital resource is available free at http://www.thermoscientific.com/lcmswater.
For the latest information about Thermo Fisher solutions and its wide range of applications for water and beverage analysis, please call +1 800 532 4752, e-mail analyze@thermofisher.com or visit www.thermoscientific.com/ms.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science. Our mission is to enable our customers to make the world healthier, cleaner and safer. With revenues of nearly $11 billion, we have approximately 37,000 employees and serve customers within pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as in environmental and process control industries. We create value for our key stakeholders through two premier brands, Thermo Scientific and Fisher Scientific, which offer a unique combination of continuous technology development and the most convenient purchasing options. Our products and services help accelerate the pace of scientific discovery, and solve analytical challenges ranging from complex research to routine testing to field applications. Visit www.thermofisher.com.
Thursday 3 November 2011
Thermo Fisher Scientific Nano-UHPLC System Significantly Increases Productivity During Proteomics Research at the University of Southern Denmark
ODENSE, Denmark (November 2, 2011) – Thermo Fisher Scientific Inc. the world leader in serving science, today announced that the Center for Experimental Bioinformatics (CEBI) at the University of Southern Denmark is using Thermo Scientific nano-ultra high performance liquid chromatography (UHPLC) technology to accelerate productivity and improve efficiencies during its proteomics research. Implementation of the Thermo Scientific EASY-nLC 1000 has enabled 34 percent more peptide and 22 percent more protein identifications within the CEBI laboratory, significantly increasing productivity. Additionally, the instrument has improved separations and facilitated the analysis of more complex samples within the laboratory.
Based in Odense, the University of Southern Denmark’s Department of Biochemistry and Molecular Biology is world-renowned in the field of proteomics, with research focusing on gene structure and organization, regulation and RNA translation. CEBI is a specialist proteomics research laboratory, aimed at applying modern methods of mass spectrometry and proteomics to functional analysis of genes.
Prior to implementing nano-UHPLC technology, CEBI used conventional HPLC. However they needed a more complete solution, such as EASY-nLC 1000, to accelerate productivity and improve efficiencies. The EASY-nLC 1000 is used in conjunction with Thermo Scientific ion trap and Orbitrap mass spectrometers for a wide range of proteomics research, including the study of complex mouse dendritic cells.
Using the EASY-nLC 1000 has allowed CEBI to take advantage of the unique ability to facilitate dedicated separation of biomolecules at ultra-high pressures. The higher operating pressures provided by the EASY-nLC 1000 have increased the number of peptide and protein identifications performed within the laboratory by 34 percent and 22 percent respectively. The instrument also allows selection of the most appropriate column dimensions and solid phase materials in order to identify the most suitable configuration to match analytical requirements. Using thinner, longer columns and smaller beads has improved separation and ionization, enhancing sensitivity and allowing the CEBI team to scale down experiments and reduce costs.
“The EASY-nLC 1000 is a highly robust instrument offering nano-UHPLC performance dedicated to proteomics scientists,” said Lasse Falkenby, research assistant at CEBI. “We decided to implement the new system in our laboratory as we felt that it would revolutionize the way we perform LC-MS analyses. The instrument has allowed our laboratory to increase productivity considerably in a way that would never have been possible before. Implementation was a very smooth process requiring minimal configuration effort and the Thermo Fisher Scientific team of experts provided valuable support both throughout and after this process.”
For more information on the Thermo Scientific EASY-nLC 1000, please visit www.thermoscientific.com/easylc, call (781) 933-4689 or e-mail analyze@thermofisher.com.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science. Our mission is to enable our customers to make the world healthier, cleaner and safer. With revenues of nearly $11 billion, we have approximately 37,000 employees and serve customers within pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as in environmental and process control industries. We create value for our key stakeholders through two premier brands, Thermo Scientific and Fisher Scientific, which offer a unique combination of continuous technology development and the most convenient purchasing options. Our products and services help accelerate the pace of scientific discovery, and solve analytical challenges ranging from complex research to routine testing to field applications. Visit www.thermofisher.com
Based in Odense, the University of Southern Denmark’s Department of Biochemistry and Molecular Biology is world-renowned in the field of proteomics, with research focusing on gene structure and organization, regulation and RNA translation. CEBI is a specialist proteomics research laboratory, aimed at applying modern methods of mass spectrometry and proteomics to functional analysis of genes.
Prior to implementing nano-UHPLC technology, CEBI used conventional HPLC. However they needed a more complete solution, such as EASY-nLC 1000, to accelerate productivity and improve efficiencies. The EASY-nLC 1000 is used in conjunction with Thermo Scientific ion trap and Orbitrap mass spectrometers for a wide range of proteomics research, including the study of complex mouse dendritic cells.
Using the EASY-nLC 1000 has allowed CEBI to take advantage of the unique ability to facilitate dedicated separation of biomolecules at ultra-high pressures. The higher operating pressures provided by the EASY-nLC 1000 have increased the number of peptide and protein identifications performed within the laboratory by 34 percent and 22 percent respectively. The instrument also allows selection of the most appropriate column dimensions and solid phase materials in order to identify the most suitable configuration to match analytical requirements. Using thinner, longer columns and smaller beads has improved separation and ionization, enhancing sensitivity and allowing the CEBI team to scale down experiments and reduce costs.
“The EASY-nLC 1000 is a highly robust instrument offering nano-UHPLC performance dedicated to proteomics scientists,” said Lasse Falkenby, research assistant at CEBI. “We decided to implement the new system in our laboratory as we felt that it would revolutionize the way we perform LC-MS analyses. The instrument has allowed our laboratory to increase productivity considerably in a way that would never have been possible before. Implementation was a very smooth process requiring minimal configuration effort and the Thermo Fisher Scientific team of experts provided valuable support both throughout and after this process.”
For more information on the Thermo Scientific EASY-nLC 1000, please visit www.thermoscientific.com/easylc, call (781) 933-4689 or e-mail analyze@thermofisher.com.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science. Our mission is to enable our customers to make the world healthier, cleaner and safer. With revenues of nearly $11 billion, we have approximately 37,000 employees and serve customers within pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as in environmental and process control industries. We create value for our key stakeholders through two premier brands, Thermo Scientific and Fisher Scientific, which offer a unique combination of continuous technology development and the most convenient purchasing options. Our products and services help accelerate the pace of scientific discovery, and solve analytical challenges ranging from complex research to routine testing to field applications. Visit www.thermofisher.com
Tuesday 1 November 2011
Thermo Fisher Scientific Showcases End-to-End Solutions for Biobanks and Biorepositories at ESBB 2011
The Turnkey Biobanking Solution Ensures Biospecimen Quality, Improves Efficiency and Fosters Information Sharing
PHILADELPHIA (November 1 2011) – Thermo Fisher Scientific Inc., the world leader in serving science, today announced it will showcase its turnkey biobanking solution within booths 13 and 14 at ESBB 2011, taking place from November 16-19, in Marseille, France. This comprehensive solution set ensures sample quality and addresses the complete biobanking workflow including biospecimen collection, processing, testing and storage, as well as sample and data management.
Thermo Scientific solutions address the unique and complex needs of biobanks and biorepositories while offering scalability and efficiency to organizations of all sizes, from university research labs to contract research organizations, laboratories and large-scale pharmaceutical and biotechnology facilities. The company delivers the software, equipment, consumables, reagents and services to provide the end-to-end solution required for today’s rapidly changing organizations.
With solutions from both the Thermo Scientific and Fisher BioServices brands, the integrated biobanking portfolio encompasses everything from sample preparation (centrifuges and laminar flow cabinets) and liquid handling equipment (pipettes, automated liquid handling) to cold storage devices (freezers and cryogenic storage) and consumables and reagents for sample preparation, analysis and storage. The biobanking solution also includes high-end equipment such as mass spectrometers and robotics to automate the biobanking process.
Fisher BioServices is the largest biorepository, managing more than 170,000,000 samples across facilities worldwide. The Thermo Scientific Laboratory Information Management System (LIMS) for Biobanks, specifically designed to address the unique challenges of managing biospecimen collection, location, online requests (including consent management and request management), chain of custody, data compliance and security, instrument integration and automation, and client billing, is used to manage this vast biorepository.
“Today, cross-disciplinary collaboration among peers is imperative, and many organizations are extending their reach to collaborate with university hospitals, pharmaceutical and biotech companies, contract research organizations and biobanks. This creates complexity as data and reports must be aggregated in a timely fashion without compromises in accuracy,” said Dave Champagne, vice president and general manager, Informatics, Thermo Fisher. “Our turnkey biobanking portfolio fosters collaboration and sharing so our customers can focus on advancing science and making life-saving discoveries.”
Thermo Scientific and Fisher BioServices solutions within booths 13 and 14 at ESBB include:
- Thermo Scientific LIMS for Biobanks. Biobanks require an advanced LIMS to manage biospecimen locations, online request management, data compliance and security, instrument integration, chain of custody and client billing. Thermo Scientific LIMS for Biobanks enables an integrated research information network by improving sample management and facilitating flawless transmission of data between different laboratories, partner organizations and the FDA. Standardizing on a single LIMS solution is a means of achieving easy data sharing and public access to findings.
- Biorepository Services. Fisher BioServices is the world leader in biological specimen management for the life science and clinical research industries. Its global capabilities comprise collection to repository, including transportation, inventory, biorepository services, biological lab processing and other support services. Through Fisher BioServices, the company can store BSL-3 materials, environmental samples, cell lines, tissues and blood products in facilities that are compliant with current good manufacturing laboratory and tissue practices (cGMP, cGLP, cGTP).
- Cold Storage and Freezers: Researchers worldwide protect more than two billion samples inside Thermo Scientific cold storage equipment. The company’s proven cold storage sample protection solutions range from +4C high-performance lab refrigerators to -196C cryogenic freezers. New at ESBB will be the Thermo Scientific Dense Storage system for low-temperature storage of biological samples and solutions. The system combines 1 mL Thermo Scientific Nunc CryoBank tubes with the new 13 x 13 tube dividers and Nunc™ CryoBoxes. This novel Dense Storage format effectively doubles existing storage capacity, which can reduce costs by up to 50 percent while decreasing energy use. Thermo Scientific freezers maximize sample storage capacity while minimizing the freezer’s footprint inside the lab. Five new capacities range in size from 421 - 949 liters (14.9 - 33.5 cu. ft.) and provide a number of options to suit any storage and lab space requirements. The new cabinet design and vacuum panel insulation permit storage of up to 70,000 2mL tubes or 118,300 1mL Thermo Scientific Cryobank tubes.
- Sample Storage and Automation: Integral 2D barcoded tubes and 2D readers offer a unique identifier for all samples, and the barcode scanner software is fully embedded and integrated with Thermo Scientific LIMS, allowing for a more streamlined workflow and automated data management for all samples. New at ESBB is the Thermo Scientific ID Scribe Labware Identifier for consistent and legible labeling of storage tubes, vials and other common labware. By removing the need for hand-labeling, sample misidentification is eliminated and laboratory efficiency is improved.
Also at ESBB, Thermo Fisher will present two workshops: “Efficient Storage of Biological Samples – How to store more samples in your freezer” and “Where In The World Are My Samples.”
For more information about Thermo Scientific solutions for biobanks and biorepositories, visit www.thermoscientific.com/biobankingresources, call +1 866 463 6522 (U.S.), +44 161 942 3000 (EU), +31 (0)76 579 5555 (Breda), e-mail marketing.informatics@thermofisher.com or visit www.thermoscientific.com/informatics.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science. Our mission is to enable our customers to make the world healthier, cleaner and safer. With revenues of nearly $11 billion, we have approximately 37,000 employees and serve customers within pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as in environmental and process control industries. We create value for our key stakeholders through two premier brands, Thermo Scientific and Fisher Scientific, which offer a unique combination of continuous technology development and the most convenient purchasing options. Our products and services help accelerate the pace of scientific discovery, and solve analytical challenges ranging from complex research to routine testing to field applications. Visit www.thermofisher.com.
PHILADELPHIA (November 1 2011) – Thermo Fisher Scientific Inc., the world leader in serving science, today announced it will showcase its turnkey biobanking solution within booths 13 and 14 at ESBB 2011, taking place from November 16-19, in Marseille, France. This comprehensive solution set ensures sample quality and addresses the complete biobanking workflow including biospecimen collection, processing, testing and storage, as well as sample and data management.
Thermo Scientific solutions address the unique and complex needs of biobanks and biorepositories while offering scalability and efficiency to organizations of all sizes, from university research labs to contract research organizations, laboratories and large-scale pharmaceutical and biotechnology facilities. The company delivers the software, equipment, consumables, reagents and services to provide the end-to-end solution required for today’s rapidly changing organizations.
With solutions from both the Thermo Scientific and Fisher BioServices brands, the integrated biobanking portfolio encompasses everything from sample preparation (centrifuges and laminar flow cabinets) and liquid handling equipment (pipettes, automated liquid handling) to cold storage devices (freezers and cryogenic storage) and consumables and reagents for sample preparation, analysis and storage. The biobanking solution also includes high-end equipment such as mass spectrometers and robotics to automate the biobanking process.
Fisher BioServices is the largest biorepository, managing more than 170,000,000 samples across facilities worldwide. The Thermo Scientific Laboratory Information Management System (LIMS) for Biobanks, specifically designed to address the unique challenges of managing biospecimen collection, location, online requests (including consent management and request management), chain of custody, data compliance and security, instrument integration and automation, and client billing, is used to manage this vast biorepository.
“Today, cross-disciplinary collaboration among peers is imperative, and many organizations are extending their reach to collaborate with university hospitals, pharmaceutical and biotech companies, contract research organizations and biobanks. This creates complexity as data and reports must be aggregated in a timely fashion without compromises in accuracy,” said Dave Champagne, vice president and general manager, Informatics, Thermo Fisher. “Our turnkey biobanking portfolio fosters collaboration and sharing so our customers can focus on advancing science and making life-saving discoveries.”
Thermo Scientific and Fisher BioServices solutions within booths 13 and 14 at ESBB include:
- Thermo Scientific LIMS for Biobanks. Biobanks require an advanced LIMS to manage biospecimen locations, online request management, data compliance and security, instrument integration, chain of custody and client billing. Thermo Scientific LIMS for Biobanks enables an integrated research information network by improving sample management and facilitating flawless transmission of data between different laboratories, partner organizations and the FDA. Standardizing on a single LIMS solution is a means of achieving easy data sharing and public access to findings.
- Biorepository Services. Fisher BioServices is the world leader in biological specimen management for the life science and clinical research industries. Its global capabilities comprise collection to repository, including transportation, inventory, biorepository services, biological lab processing and other support services. Through Fisher BioServices, the company can store BSL-3 materials, environmental samples, cell lines, tissues and blood products in facilities that are compliant with current good manufacturing laboratory and tissue practices (cGMP, cGLP, cGTP).
- Cold Storage and Freezers: Researchers worldwide protect more than two billion samples inside Thermo Scientific cold storage equipment. The company’s proven cold storage sample protection solutions range from +4C high-performance lab refrigerators to -196C cryogenic freezers. New at ESBB will be the Thermo Scientific Dense Storage system for low-temperature storage of biological samples and solutions. The system combines 1 mL Thermo Scientific Nunc CryoBank tubes with the new 13 x 13 tube dividers and Nunc™ CryoBoxes. This novel Dense Storage format effectively doubles existing storage capacity, which can reduce costs by up to 50 percent while decreasing energy use. Thermo Scientific freezers maximize sample storage capacity while minimizing the freezer’s footprint inside the lab. Five new capacities range in size from 421 - 949 liters (14.9 - 33.5 cu. ft.) and provide a number of options to suit any storage and lab space requirements. The new cabinet design and vacuum panel insulation permit storage of up to 70,000 2mL tubes or 118,300 1mL Thermo Scientific Cryobank tubes.
- Sample Storage and Automation: Integral 2D barcoded tubes and 2D readers offer a unique identifier for all samples, and the barcode scanner software is fully embedded and integrated with Thermo Scientific LIMS, allowing for a more streamlined workflow and automated data management for all samples. New at ESBB is the Thermo Scientific ID Scribe Labware Identifier for consistent and legible labeling of storage tubes, vials and other common labware. By removing the need for hand-labeling, sample misidentification is eliminated and laboratory efficiency is improved.
Also at ESBB, Thermo Fisher will present two workshops: “Efficient Storage of Biological Samples – How to store more samples in your freezer” and “Where In The World Are My Samples.”
For more information about Thermo Scientific solutions for biobanks and biorepositories, visit www.thermoscientific.com/biobankingresources, call +1 866 463 6522 (U.S.), +44 161 942 3000 (EU), +31 (0)76 579 5555 (Breda), e-mail marketing.informatics@thermofisher.com or visit www.thermoscientific.com/informatics.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science. Our mission is to enable our customers to make the world healthier, cleaner and safer. With revenues of nearly $11 billion, we have approximately 37,000 employees and serve customers within pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as in environmental and process control industries. We create value for our key stakeholders through two premier brands, Thermo Scientific and Fisher Scientific, which offer a unique combination of continuous technology development and the most convenient purchasing options. Our products and services help accelerate the pace of scientific discovery, and solve analytical challenges ranging from complex research to routine testing to field applications. Visit www.thermofisher.com.
Thursday 27 October 2011
Analytical Technology is Awarded Prestigious Framework Agreement with Yorkshire Water
Manchester, UK (October 27, 2011) Specialist electrochemical sensor manufacturer Analytical Technology Inc. today announces that it has been awarded a framework agreement to supply and install bufferless chlorine monitoring systems to Yorkshire Water. An in-depth technical evaluation was carried out by Yorkshire Water, in which Analytical Technology’s products were compared with a competitor’s against benchmark buffered units. Following this extensive process, Analytical Technology secured the agreement and commenced an asset replacement scheme for over 450 chlorine monitors.
The evaluation period lasted eight months and Analytical Technology’s bufferless chlorine monitors were tested using a wide variety of water types at four different water treatment works. During this time, the Analytical Technology monitors required very little maintenance and calibration, reflecting the company’s vast experience with membrane technology. This trial established that the monitor’s membranes would not need replacing for at least six months at all but a small minority of sites with high manganese levels.
Yorkshire Water continually monitors water from its 59 treatment plants with samples taken from 363 reservoirs where treated water is stored. In a typical year, more than 500,000 tests are carried out on water samples to ensure it meets exacting standards. The first phase of Analytical Technology’s framework agreement has been successfully completed with 75 chlorine monitors installed at 12 Yorkshire Water sites in the North and Dales areas. This includes a mixture of buffered, bufferless and pH corrected units, which are deployed depending on water quality and expected pH range. Additionally, funding for the second phase has recently been approved, in which a region wide asset replacement of chlorine monitors will be completed. This will include the installation of 377 chlorine monitors into an additional 31 water treatment plants and 20 secondary chlorination sites.
Rod Black, Asset Reliability Manager at Yorkshire Water said: “The instruments have performed well with little or no issues; chlorine control has been good and has not contributed to any call outs. It is nice to have standard instruments which can be calibrated and cleaned easily.” Alan Henson, Project Manager at Yorkshire Water commented: “Analytical Technology came out comfortably the best performer in our rigorous selection process, and the company’s vast experience with membrane technology places them ahead of most of their competitors who are only just adopting the technology. Once the roll-out has been completed, the scheme will have realised around £335K of OPEX savings per annum for Yorkshire Water and operators will no longer have to manhandle 25 litre containers of buffer around our sites. Analytical Technology has provided an excellent service and it is a pleasure working with a company who are very customer focussed.”
Dr. Michael Strahand, General Manager Europe at Analytical Technology added: “This agreement confirms that Analytical Technology’s chlorine monitors are unrivalled in the market, maintaining our position as one of the leading suppliers of water monitoring systems in the UK. Our top quality instrumentation is backed up by our commitment to delivering industry leading customer service and this new framework agreement is a great reward for our hard-working and dedicated team.”
Analytical Technology is a UK and European specialist electrochemical sensor manufacturer that supplies both water and gas monitoring instrumentation. The company was set up in 1998 and from then on has enjoyed increasing success. This new framework agreement to supply bufferless chlorine monitors to Yorkshire Water now means Analytical Technology provides instrumentation to 7 out of the 10 major utility companies in the UK. Analytical Technology’s wide range of water monitors includes peracetic acid, hydrogen peroxide, residual sulphite and several chlorine monitors. The company’s products aim to provide simpler installation, easier operation, regulatory compliance and lower cost, all combined with first class customer service.
For more information on Analytical Technology’s water and gas monitoring instrumentation, please call +44(0)1457 873 318, e-mail sales@atiuk.com or visit www.analyticaltechnology.com.
For further press information please contact: Lindsay Baldry, The Scott Partnership, 1 Whiteside, Station Road, Holmes Chapel, Cheshire CW4 8AA Tel: +44 1477 539539 Fax: +44 1477 539540 e-mail: ati@scottpr.com
The evaluation period lasted eight months and Analytical Technology’s bufferless chlorine monitors were tested using a wide variety of water types at four different water treatment works. During this time, the Analytical Technology monitors required very little maintenance and calibration, reflecting the company’s vast experience with membrane technology. This trial established that the monitor’s membranes would not need replacing for at least six months at all but a small minority of sites with high manganese levels.
Yorkshire Water continually monitors water from its 59 treatment plants with samples taken from 363 reservoirs where treated water is stored. In a typical year, more than 500,000 tests are carried out on water samples to ensure it meets exacting standards. The first phase of Analytical Technology’s framework agreement has been successfully completed with 75 chlorine monitors installed at 12 Yorkshire Water sites in the North and Dales areas. This includes a mixture of buffered, bufferless and pH corrected units, which are deployed depending on water quality and expected pH range. Additionally, funding for the second phase has recently been approved, in which a region wide asset replacement of chlorine monitors will be completed. This will include the installation of 377 chlorine monitors into an additional 31 water treatment plants and 20 secondary chlorination sites.
Rod Black, Asset Reliability Manager at Yorkshire Water said: “The instruments have performed well with little or no issues; chlorine control has been good and has not contributed to any call outs. It is nice to have standard instruments which can be calibrated and cleaned easily.” Alan Henson, Project Manager at Yorkshire Water commented: “Analytical Technology came out comfortably the best performer in our rigorous selection process, and the company’s vast experience with membrane technology places them ahead of most of their competitors who are only just adopting the technology. Once the roll-out has been completed, the scheme will have realised around £335K of OPEX savings per annum for Yorkshire Water and operators will no longer have to manhandle 25 litre containers of buffer around our sites. Analytical Technology has provided an excellent service and it is a pleasure working with a company who are very customer focussed.”
Dr. Michael Strahand, General Manager Europe at Analytical Technology added: “This agreement confirms that Analytical Technology’s chlorine monitors are unrivalled in the market, maintaining our position as one of the leading suppliers of water monitoring systems in the UK. Our top quality instrumentation is backed up by our commitment to delivering industry leading customer service and this new framework agreement is a great reward for our hard-working and dedicated team.”
Analytical Technology is a UK and European specialist electrochemical sensor manufacturer that supplies both water and gas monitoring instrumentation. The company was set up in 1998 and from then on has enjoyed increasing success. This new framework agreement to supply bufferless chlorine monitors to Yorkshire Water now means Analytical Technology provides instrumentation to 7 out of the 10 major utility companies in the UK. Analytical Technology’s wide range of water monitors includes peracetic acid, hydrogen peroxide, residual sulphite and several chlorine monitors. The company’s products aim to provide simpler installation, easier operation, regulatory compliance and lower cost, all combined with first class customer service.
For more information on Analytical Technology’s water and gas monitoring instrumentation, please call +44(0)1457 873 318, e-mail sales@atiuk.com or visit www.analyticaltechnology.com.
For further press information please contact: Lindsay Baldry, The Scott Partnership, 1 Whiteside, Station Road, Holmes Chapel, Cheshire CW4 8AA Tel: +44 1477 539539 Fax: +44 1477 539540 e-mail: ati@scottpr.com
Monday 24 October 2011
Exco InTouch Wins Deloitte Technology Fast 50 Award in Recognition of Significant Growth
(Sawbridgeworth, UK, October 24 2011) Exco InTouch, the leading provider of patient communication solutions for the pharmaceutical and healthcare sectors, today announced that it is a winner of the 2011 Deloitte Technology Fast 50. The awards, now in their 14th year, are an independent ranking of the 50 fastest growing technology companies in the UK, based on percentage growth in revenue over five years. Exco InTouch was placed as the 44th fastest growing company in the country and the 7th fastest growing company in the South East region. Receipt of the Fast 50 award is a significant achievement, recognising growth based on innovation and entrepreneurship. Exco InTouch’s win comes on the back of a recent growth investment from leading growth equity and venture capital group Scottish Equity Partners (SEP).
Exco InTouch, whose clients include nine of the world’s top 10 pharmaceutical businesses, offers an innovative suite of patient-focused services which are delivered using a combination of cell-phone and internet technology. Used in clinical trials, the company’s services benefit both patients and pharmaceutical clients, providing patient recruitment and retention support. These unique services result in improved overall compliance and the facilitation of the electronic capture of patient reported outcomes data (ePRO) during clinical trials and in Late Phase observational studies. The business, which employs some 40 staff, has its headquarters in the UK and offices in the United States and recently opened a second UK office in Nottingham to accommodate up to 30 more staff.
With the recent £3m investment from SEP, Exco InTouch is entering its next growth phase, enabling it to invest further in people, technology and infrastructure and to further enhance its revolutionary mobile technology platform. SEP has taken a minority stake in the company. Exco InTouch will use the funds to take advantage of significant growth opportunities in the clinical trial sector, particularly in the emerging mobile patient communication market. Demand for its services is growing exponentially as pharmaceutical companies are increasingly adopting smart technology to optimise clinical trial execution.
“Making the Deloitte Technology Fast 50 is a testament to a company’s commitment to technology”, says Mark Doleman, Regional Partner, Deloitte UK Technology Fast 50 and Technology Fast 500 EMEA Programmes. “With its 730% growth rate over five years, Exco InTouch has proven that its leadership has the vision and determination to grow in competitive conditions.”
“The Deloitte UK Technology Fast 50 is internationally recognised as being one of the most important business awards in the sector and we are thrilled to receive this accreditation”, comments Tim Davis, CEO of Exco InTouch. “Despite economic uncertainty, the past five years have proved highly successful for us, with particular growth in our ePRO and patient engagement services. We look forward to this continued growth in the future as sponsors increasingly recognise the benefits of our mobile technology in the healthcare and drug development sectors.”
For further information on the Exco InTouch range of solutions, please call +44 1279 709 040 or +1 877 327 5777 or visit www.excointouch.com.
For further press information please contact: Fiona Robinson, The Scott Partnership, 1 Whiteside, Station Road, Holmes Chapel, Cheshire CW4 8AA Tel: +44 1477 539539 Fax: +44 1477 539540 e-mail: exco@scottpr.com
About Exco InTouch:
Exco InTouch is the leading provider of regulatory compliant interactive mobile patient communication solutions for Patient Recruitment, Retention, Compliance, ePRO/eDiary and Late Phase studies. Using a combination of software and services, Exco InTouch solutions provide simple, quick and non-intrusive channels of communication that enables sponsors, CROs, sites and patient recruitment agencies, find the right patients; keep them in their studies; motivate them to maintain full compliance and facilitate the collection of quality patient data, thus ensuring a better overall patient experience.
These solutions are currently being used by hundreds of thousands of patients in over 70 countries, delivered in the local language and are fully compliant with HIPAA regulations, FDA CFR 21 Part 11 and all electronic communication privacy directives.
About Deloitte:
In this press release references to Deloitte are references to Deloitte LLP, which is among the country's leading professional services firms.
Deloitte LLP is the United Kingdom member firm of Deloitte Touche Tohmatsu (‘DTT’), a Swiss Verein, whose member firms are legally separate and independent entities. Please see www.deloitte.co.uk/about for a detailed description of the legal structure of DTT and its member firms.
The information contained in this press release is correct at the time of going to press.
For more information, please visit www.deloitte.co.uk.
Deloitte Technology, Media & Telecommunications (TMT) Group
The Deloitte TMT Group is composed of service professionals who have a wealth of experience serving technology, media and telecommunications companies throughout the UK in areas including cable, communications providers, computers and peripherals, entertainment, media and publishing, networking, semiconductors, software, wireless, and related industries. These specialists understand the challenges that these companies face throughout all stages of their business growth cycle and are committed to helping them succeed. Deloitte is a leader in providing strategic, financial and operational assistance to its technology, media and telecommunications clients.
For more information, please visit www.deloitte.co.uk/tmt
Exco InTouch, whose clients include nine of the world’s top 10 pharmaceutical businesses, offers an innovative suite of patient-focused services which are delivered using a combination of cell-phone and internet technology. Used in clinical trials, the company’s services benefit both patients and pharmaceutical clients, providing patient recruitment and retention support. These unique services result in improved overall compliance and the facilitation of the electronic capture of patient reported outcomes data (ePRO) during clinical trials and in Late Phase observational studies. The business, which employs some 40 staff, has its headquarters in the UK and offices in the United States and recently opened a second UK office in Nottingham to accommodate up to 30 more staff.
With the recent £3m investment from SEP, Exco InTouch is entering its next growth phase, enabling it to invest further in people, technology and infrastructure and to further enhance its revolutionary mobile technology platform. SEP has taken a minority stake in the company. Exco InTouch will use the funds to take advantage of significant growth opportunities in the clinical trial sector, particularly in the emerging mobile patient communication market. Demand for its services is growing exponentially as pharmaceutical companies are increasingly adopting smart technology to optimise clinical trial execution.
“Making the Deloitte Technology Fast 50 is a testament to a company’s commitment to technology”, says Mark Doleman, Regional Partner, Deloitte UK Technology Fast 50 and Technology Fast 500 EMEA Programmes. “With its 730% growth rate over five years, Exco InTouch has proven that its leadership has the vision and determination to grow in competitive conditions.”
“The Deloitte UK Technology Fast 50 is internationally recognised as being one of the most important business awards in the sector and we are thrilled to receive this accreditation”, comments Tim Davis, CEO of Exco InTouch. “Despite economic uncertainty, the past five years have proved highly successful for us, with particular growth in our ePRO and patient engagement services. We look forward to this continued growth in the future as sponsors increasingly recognise the benefits of our mobile technology in the healthcare and drug development sectors.”
For further information on the Exco InTouch range of solutions, please call +44 1279 709 040 or +1 877 327 5777 or visit www.excointouch.com.
For further press information please contact: Fiona Robinson, The Scott Partnership, 1 Whiteside, Station Road, Holmes Chapel, Cheshire CW4 8AA Tel: +44 1477 539539 Fax: +44 1477 539540 e-mail: exco@scottpr.com
About Exco InTouch:
Exco InTouch is the leading provider of regulatory compliant interactive mobile patient communication solutions for Patient Recruitment, Retention, Compliance, ePRO/eDiary and Late Phase studies. Using a combination of software and services, Exco InTouch solutions provide simple, quick and non-intrusive channels of communication that enables sponsors, CROs, sites and patient recruitment agencies, find the right patients; keep them in their studies; motivate them to maintain full compliance and facilitate the collection of quality patient data, thus ensuring a better overall patient experience.
These solutions are currently being used by hundreds of thousands of patients in over 70 countries, delivered in the local language and are fully compliant with HIPAA regulations, FDA CFR 21 Part 11 and all electronic communication privacy directives.
About Deloitte:
In this press release references to Deloitte are references to Deloitte LLP, which is among the country's leading professional services firms.
Deloitte LLP is the United Kingdom member firm of Deloitte Touche Tohmatsu (‘DTT’), a Swiss Verein, whose member firms are legally separate and independent entities. Please see www.deloitte.co.uk/about for a detailed description of the legal structure of DTT and its member firms.
The information contained in this press release is correct at the time of going to press.
For more information, please visit www.deloitte.co.uk.
Deloitte Technology, Media & Telecommunications (TMT) Group
The Deloitte TMT Group is composed of service professionals who have a wealth of experience serving technology, media and telecommunications companies throughout the UK in areas including cable, communications providers, computers and peripherals, entertainment, media and publishing, networking, semiconductors, software, wireless, and related industries. These specialists understand the challenges that these companies face throughout all stages of their business growth cycle and are committed to helping them succeed. Deloitte is a leader in providing strategic, financial and operational assistance to its technology, media and telecommunications clients.
For more information, please visit www.deloitte.co.uk/tmt
Tameside Hospital and Synergy Health Extend Partnership With Sterile Services Contract
Swindon, UK (24 October 2011) – Synergy Health, the leading provider of specialist outsourced services to healthcare providers, today announced that Tameside Hospital NHS Foundation Trust has renewed its relationship with the company with the signing of a sterile services agreement. The lifetime contract, worth approximately £5m, is a continuation of the long standing relationship between the two organizations. Synergy Health delivers a range of specialist outsourced services to healthcare providers across Europe and China. These services are aimed at supporting customers to improve the quality and efficiency of their activities, while reducing risks to patients and clients. This continued collaboration will allow the Trust to benefit from enhanced productivity.
The Trust runs Tameside Hospital in Ashton-Under-Lyne, Synergy Health has been running the Trust’s sterile service processing facilities for over ten years.
Thursday 20 October 2011
Synergy Health Hires Specialist Business Development Manager in Line with Continued Growth Strategy
Swindon, UK (20th October 2011) – Synergy Health, the leading provider of specialist outsourced services to healthcare providers, today announced the appointment of Steve Poynter as Business Development Manager. The new role is part of Synergy Health’s growth strategy and is in response to increased demand for its services.
Poynter’s extensive health experience will be put to good use helping the NHS to maximize limited resources while improving quality and safety. Recent successful partnerships based on this model include University Hospital Leicester, Sheffield, Knowsley and The Royal London with Synergy Health providing the decontamination of surgical instruments, which demonstrate how investment in expertise and collaboration results in increased patient safety and cost savings.
Tuesday 18 October 2011
Optibrium Expands StarDrop Availability with Apple Mac Compatibility
Delivering Enhanced Functionality to Guide Decisions in All Stages of Drug Discovery
CAMBRIDGE, UK, October 18, 2011 – Optibrium, a provider of software solutions for drug discovery, today launches StarDrop 5.1, an upgraded version of its innovative support tool which helps drug discovery scientists to guide key decisions in drug discovery and quickly achieve successful project outcomes. As a result of this upgrade, StarDrop’s unique capabilities to guide the design and selection of high quality, novel compounds are now available on the Apple Mac, a reflection of the increasing popularity of Macs within the industry.
The revolutionary StarDrop 5.1 is a powerful yet user friendly software package which combines predictive capabilities with intuitive approaches to quickly and confidently target compounds with a good balance of properties, thereby reducing wasted effort and speeding progress to identify effective lead and candidate drugs. StarDrop’s unique approach to ‘multi-parameter optimisation’ explicitly accounts for the uncertainty in drug discovery data, whether due to experimental variability or predictive error, to provide scientists with a rigorous, objective analysis on which to make rational decisions.
As well as compatibility with the Apple Mac, StarDrop 5.1 brings a number of significant enhancements to existing features of StarDrop. For example, there is a new method for creating ‘chemical space’ visualizations based on the latest machine learning algorithm for ‘visual clustering’, that helps to easily explore the diversity of a project’s chemistry and identify ‘hot spots’ of high quality chemistry for further investigation.
There are also improvements to StarDrop’s plug-in modules: The Auto-Modeller™ sees the addition of the ‘Random Forests’ technique to its extensive repertoire for building predictive models tailored to a project’s chemistry and data. The addition of this new method has also led to improved QSAR models in the ADME QSAR module, which provides predictions of key ADME properties. StarDrop’s P450 metabolism module has been upgraded to provide improved prediction of regioselectivity and lability of metabolism by Cytochrome P450 enzymes, specifically around N-oxidation pathways. Finally, in response to user feedback on the new Nova™ module, further advances allow the generation of novel, relevant compounds ideas, prioritised against a project’s required property profile, starting from multiple initial structures and filtered according to user-specified rules to avoid unwanted substructures.
Dr. Matthew Segall, CEO of Optibrium, explains “These latest developments within StarDrop 5.1 demonstrate Optibrium’s commitment to deliver leading-edge technology while simultaneously responding to user feedback in order to ensure that it is accessible in the most user-friendly way. We work with drug discovery scientists, project leaders and R&D directors to provide tools that support confident decision-making to focus resources and improve efficiency.”
For more information about StarDrop 5.1 and Optibrium’s software solutions please visit www.optibrium.com, alternatively please call +44 (0) 1223 815 900 or email info@optibrium.com
About Optibrium Ltd
Optibrium (www.optibrium.com) is dedicated to providing software to guide decisions involving complex, uncertain data in an intuitive way. Based in Cambridge, UK, Optibrium has a global customer base ranging from top-ten pharmaceutical companies to small biotechs and academic groups. Our mission is to continue to develop new technologies that will optimise project strategy, reduce wasted molecules and experiments, shorten timelines and improve the quality of candidate compounds for our clients. Optibrium’s primary product, StarDrop, is focused on the drug discovery industry, helping guide scientists to make decisions in the design and selection of high quality drug candidates. Visit the online community at http://www.optibrium.com/community/ for further discussions on improving the productivity of drug discovery.
For further press information please contact: Sarah Evans, The Scott Partnership, 1 Whiteside, Station Road, Holmes Chapel, Cheshire CW4 8AA, UK Tel: + 44 1477 539539 Fax: +44 1477 539 540 E-mail: optibrium@scottpr.com
CAMBRIDGE, UK, October 18, 2011 – Optibrium, a provider of software solutions for drug discovery, today launches StarDrop 5.1, an upgraded version of its innovative support tool which helps drug discovery scientists to guide key decisions in drug discovery and quickly achieve successful project outcomes. As a result of this upgrade, StarDrop’s unique capabilities to guide the design and selection of high quality, novel compounds are now available on the Apple Mac, a reflection of the increasing popularity of Macs within the industry.
The revolutionary StarDrop 5.1 is a powerful yet user friendly software package which combines predictive capabilities with intuitive approaches to quickly and confidently target compounds with a good balance of properties, thereby reducing wasted effort and speeding progress to identify effective lead and candidate drugs. StarDrop’s unique approach to ‘multi-parameter optimisation’ explicitly accounts for the uncertainty in drug discovery data, whether due to experimental variability or predictive error, to provide scientists with a rigorous, objective analysis on which to make rational decisions.
As well as compatibility with the Apple Mac, StarDrop 5.1 brings a number of significant enhancements to existing features of StarDrop. For example, there is a new method for creating ‘chemical space’ visualizations based on the latest machine learning algorithm for ‘visual clustering’, that helps to easily explore the diversity of a project’s chemistry and identify ‘hot spots’ of high quality chemistry for further investigation.
There are also improvements to StarDrop’s plug-in modules: The Auto-Modeller™ sees the addition of the ‘Random Forests’ technique to its extensive repertoire for building predictive models tailored to a project’s chemistry and data. The addition of this new method has also led to improved QSAR models in the ADME QSAR module, which provides predictions of key ADME properties. StarDrop’s P450 metabolism module has been upgraded to provide improved prediction of regioselectivity and lability of metabolism by Cytochrome P450 enzymes, specifically around N-oxidation pathways. Finally, in response to user feedback on the new Nova™ module, further advances allow the generation of novel, relevant compounds ideas, prioritised against a project’s required property profile, starting from multiple initial structures and filtered according to user-specified rules to avoid unwanted substructures.
Dr. Matthew Segall, CEO of Optibrium, explains “These latest developments within StarDrop 5.1 demonstrate Optibrium’s commitment to deliver leading-edge technology while simultaneously responding to user feedback in order to ensure that it is accessible in the most user-friendly way. We work with drug discovery scientists, project leaders and R&D directors to provide tools that support confident decision-making to focus resources and improve efficiency.”
For more information about StarDrop 5.1 and Optibrium’s software solutions please visit www.optibrium.com, alternatively please call +44 (0) 1223 815 900 or email info@optibrium.com
About Optibrium Ltd
Optibrium (www.optibrium.com) is dedicated to providing software to guide decisions involving complex, uncertain data in an intuitive way. Based in Cambridge, UK, Optibrium has a global customer base ranging from top-ten pharmaceutical companies to small biotechs and academic groups. Our mission is to continue to develop new technologies that will optimise project strategy, reduce wasted molecules and experiments, shorten timelines and improve the quality of candidate compounds for our clients. Optibrium’s primary product, StarDrop, is focused on the drug discovery industry, helping guide scientists to make decisions in the design and selection of high quality drug candidates. Visit the online community at http://www.optibrium.com/community/ for further discussions on improving the productivity of drug discovery.
For further press information please contact: Sarah Evans, The Scott Partnership, 1 Whiteside, Station Road, Holmes Chapel, Cheshire CW4 8AA, UK Tel: + 44 1477 539539 Fax: +44 1477 539 540 E-mail: optibrium@scottpr.com
Monday 17 October 2011
The TSP Shanghai Office Team!
We love this picture of our TSP China team on a group day out to celebrate the end of first year trading and a successful start to Quarter One of Year Two.
From left to right: Olive Zhang, Zoe Wang, Daisy Shao, Joyce Wang, Rae Wang, Jacky Cheng, Coco Gu, Lily Liu, May Lan.
Thursday 13 October 2011
Novozymes to showcase state of the art cGMP-grade hyaluronic acid (HA) at CPhI 2011
HA designed specifically to fill a gap in the market for medical device and pharmaceutical manufacturers looking for Q7 cGMP regulatory compliant ingredients with superior performance benefits.
NOTTINGHAM, UK – October 13, 2011 – Novozymes Biopharma, part of Novozymes A/S, world leader in bioinnovation, will showcase its soon to be launched state of the art Q7 cGMP-grade hyaluronic acid (HA) at CPhI Worldwide 2011. The new Bacillus-derived HA has been developed to improve how customers process and formulate HA for medical device and pharmaceutical applications, helping to speed up product development and creating improved therapeutics. The product confers a range of unique performance advantages for medical devices, drug delivery and formulation and will be showcased on booth #42H55 in hall 4.2 at the Messe Frankfurt, October 25-27, in Frankfurt, Germany.
“Novozymes is delighted to be returning to CPhI to showcase the company’s soon to be launched Q7 cGMP HA”, comments Hans Ole Klingenberg, global marketing director at Novozymes. “Delegates will be able to see the HA and our team of experts will be on hand to provide insight into how it can be incorporated into their manufacturing processes to reduce testing time, save on manufacturing costs and take products to market faster.”
Novozymes’ HA has been developed to expand opportunities for HA across multiple applications in the pharmaceutical and medical device industries. Produced at Novozymes’ new facility in Tianjin, China, which has been designed exclusively for HA, the company uses a patented water based process which is run in compliance with ICH Q7 cGMP guidelines. The resulting HA is free of animal derived components and organic solvents, resulting in a high degree of purity and reduced risk of contamination. It offers high batch-to-batch consistency with tight control of molecular weight for improved formulation control, as well as the capability to dissolve up to five times faster than other commercially available sources of HA. In addition, superior heat stability permits autoclaving without significant loss of product viscosity.
The new HA can be customized further using Novozymes’ proprietary crosslinking technology to achieve a specified viscosity, allowing the product to be adapted for a range of drug delivery and medical device applications. From ophthalmology and dermal filling to osteoarthritis treatments and cancer treatment, the unique technology will assist customers to create improved therapeutics with real benefits for both manufacturers and patients.
Novozymes’ HA will be commercially available in December.
To learn more about Novozymes’ HA, please visit booth #42H55 in hall 4.2 at CPhI Worldwide 2011. Alternatively, please visit www.biopharma.novozymes.com.
About Novozymes
Novozymes is the world leader in bioinnovation. Together with customers across a broad array of industries, we create tomorrow’s industrial biosolutions, improving our customers' business and the use of our planet's resources.
With over 700 products used in 130 countries, Novozymes’ bioinnovations improve industrial performance and safeguard the world’s resources by offering superior and sustainable solutions for tomorrow’s ever-changing marketplace. Read more at www.novozymes.com.
NOTTINGHAM, UK – October 13, 2011 – Novozymes Biopharma, part of Novozymes A/S, world leader in bioinnovation, will showcase its soon to be launched state of the art Q7 cGMP-grade hyaluronic acid (HA) at CPhI Worldwide 2011. The new Bacillus-derived HA has been developed to improve how customers process and formulate HA for medical device and pharmaceutical applications, helping to speed up product development and creating improved therapeutics. The product confers a range of unique performance advantages for medical devices, drug delivery and formulation and will be showcased on booth #42H55 in hall 4.2 at the Messe Frankfurt, October 25-27, in Frankfurt, Germany.
“Novozymes is delighted to be returning to CPhI to showcase the company’s soon to be launched Q7 cGMP HA”, comments Hans Ole Klingenberg, global marketing director at Novozymes. “Delegates will be able to see the HA and our team of experts will be on hand to provide insight into how it can be incorporated into their manufacturing processes to reduce testing time, save on manufacturing costs and take products to market faster.”
Novozymes’ HA has been developed to expand opportunities for HA across multiple applications in the pharmaceutical and medical device industries. Produced at Novozymes’ new facility in Tianjin, China, which has been designed exclusively for HA, the company uses a patented water based process which is run in compliance with ICH Q7 cGMP guidelines. The resulting HA is free of animal derived components and organic solvents, resulting in a high degree of purity and reduced risk of contamination. It offers high batch-to-batch consistency with tight control of molecular weight for improved formulation control, as well as the capability to dissolve up to five times faster than other commercially available sources of HA. In addition, superior heat stability permits autoclaving without significant loss of product viscosity.
The new HA can be customized further using Novozymes’ proprietary crosslinking technology to achieve a specified viscosity, allowing the product to be adapted for a range of drug delivery and medical device applications. From ophthalmology and dermal filling to osteoarthritis treatments and cancer treatment, the unique technology will assist customers to create improved therapeutics with real benefits for both manufacturers and patients.
Novozymes’ HA will be commercially available in December.
To learn more about Novozymes’ HA, please visit booth #42H55 in hall 4.2 at CPhI Worldwide 2011. Alternatively, please visit www.biopharma.novozymes.com.
About Novozymes
Novozymes is the world leader in bioinnovation. Together with customers across a broad array of industries, we create tomorrow’s industrial biosolutions, improving our customers' business and the use of our planet's resources.
With over 700 products used in 130 countries, Novozymes’ bioinnovations improve industrial performance and safeguard the world’s resources by offering superior and sustainable solutions for tomorrow’s ever-changing marketplace. Read more at www.novozymes.com.
Tuesday 11 October 2011
Synergy Health (UK) Appoints The Scott Partnership to Support Hospital Sterile Services
Cheshire, UK (Date, 2011) – Global B2B strategic communications agency The Scott Partnership has been appointed by Synergy Health (UK) Ltd. to support growth in its Hospital Sterile Services division.
Synergy is a leading provider of outsourced and managed decontamination services for reprocessing surgical instruments, processing more than 60 million surgical instruments per year for Acute NHS Trusts, NHS primary care providers and healthcare operators in the private sector. With 18 sterile service facilities, Synergy is the UK’s market leader in the provision of this service.
The client is being managed by The Scott Partnership’s Healthcare division whose brief is to engage stakeholders around Synergy’s innovative operating model which improves service and instrument processing quality, while significantly reducing operating costs.
Mike Langhorn, Synergy’s Commercial Director said: “We chose The Scott Partnership for their invaluable NHS experience and wide knowledge of the healthcare sector. This makes them a valued partner in positioning our hospital sterile services as a viable solution to enhance patient safety, improve quality and reduce costs – critical to today’s NHS.”
“This welcome addition to The Scott Partnership’s portfolio is a significant step in our continued expansion - further strengthening our customer base and presence in the healthcare sector,” adds Kath Darlington, CEO. “This account very much plays to our strengths and joins many existing clients who specialise in contract outsourcing and where high-level clinical engagement is critical.”
Based near Manchester, UK, The Scott Partnership is a specialist business-to-business PR agency for the healthcare, scientific, technology and pharmaceutical industries and which has grown to become one of the leading communications consultancies in Europe. Founded in 1996, the company’s accelerated growth plan has seen it establish offices in Boston and Shanghai in the past three years as well as its recent acquisition of Kapler Communications, a Bedfordshire-based life sciences consultancy.
For more information on The Scott Partnership, please call +44 (0)1477 539 539. Alternatively e-mail business@scottpr.com or visit www.scottpr.com.
Synergy is a leading provider of outsourced and managed decontamination services for reprocessing surgical instruments, processing more than 60 million surgical instruments per year for Acute NHS Trusts, NHS primary care providers and healthcare operators in the private sector. With 18 sterile service facilities, Synergy is the UK’s market leader in the provision of this service.
The client is being managed by The Scott Partnership’s Healthcare division whose brief is to engage stakeholders around Synergy’s innovative operating model which improves service and instrument processing quality, while significantly reducing operating costs.
Mike Langhorn, Synergy’s Commercial Director said: “We chose The Scott Partnership for their invaluable NHS experience and wide knowledge of the healthcare sector. This makes them a valued partner in positioning our hospital sterile services as a viable solution to enhance patient safety, improve quality and reduce costs – critical to today’s NHS.”
“This welcome addition to The Scott Partnership’s portfolio is a significant step in our continued expansion - further strengthening our customer base and presence in the healthcare sector,” adds Kath Darlington, CEO. “This account very much plays to our strengths and joins many existing clients who specialise in contract outsourcing and where high-level clinical engagement is critical.”
Based near Manchester, UK, The Scott Partnership is a specialist business-to-business PR agency for the healthcare, scientific, technology and pharmaceutical industries and which has grown to become one of the leading communications consultancies in Europe. Founded in 1996, the company’s accelerated growth plan has seen it establish offices in Boston and Shanghai in the past three years as well as its recent acquisition of Kapler Communications, a Bedfordshire-based life sciences consultancy.
For more information on The Scott Partnership, please call +44 (0)1477 539 539. Alternatively e-mail business@scottpr.com or visit www.scottpr.com.
The World's Biggest Coffee Morning!
Last week we took part in a charity event for a very worthy cause, Macmillan Cancer Support. The coffee morning is a national event which started as a small gathering, organised by a local fundraising committee in 1990. It is now is a hugely recognised event, taking place in offices, schools, universities and fundraising societies all over the country. It has grown massively since its inception and has turned into the world’s biggest coffee morning, 43,000 people signed up and took part last year!
Monday 10 October 2011
Thermo Fisher Scientific Introduces New Informatics Solution for Water and Environmental Testing Laboratories
PHILADELPHIA (October 10, 2011) – Thermo Fisher Scientific Inc., the world leader in serving science, today announced a new informatics solution specifically developed for laboratory professionals working in water and environmental testing laboratories. The Thermo Scientific Water and Environmental LIMS is preconfigured to enable customers to comply with water and environmental regulatory guidelines and requirements, and it is built on the comprehensive functionality provided by the company’s flagship laboratory information management system, Thermo Scientific SampleManager LIMS. The company will showcase the Water and Environmental LIMS at Thermo Scientific booth # 4145 during WEFTEC 2011, being held October 17 - 19, in Los Angeles.
Friday 7 October 2011
A Day at the Races
Friday 9th September was the first decent day, weather wise, that we had seen in a while. Perfect timing as it was the day of The Scott Partnership’s trip to the Chester Races. Our southern partners Kapler, along with our sister company Scott Brothers Ltd. came along for the day which made it a big day out. After an excited morning at work, we piled onto the coach at lunchtime clutching our copies of the daily Racing Post in hope of winning some money. On the coach we were given our county concourse badges for admission which allowed us access to more of the course than most other ticket options. We were able to see the Paddocks Parade Ring and the Winners Enclosure, as well as having access to fine dining, various bars and an exclusive champagne bar. A pretty good deal I’d say!
Thursday 6 October 2011
Thermo Fisher Scientific Leading Mass Spectrometry Systems Selected by CVUA-MEL to Ensure Food Safety with Rapid and Reliable Contaminant Analysis
SAN JOSE, California (October 05, 2011) – Thermo Fisher Scientific Inc., the world leader in serving science, today announced that the Chemical and Veterinary Analytical Institute Münsterland-Emscher-Lippe (CVUA-MEL) has standardized on Thermo Scientific LC-MS and GC-MS systems for routine analyses of contaminants in food, feed and human samples. The CVUA-MEL requires extremely high resolution and highly sensitive instruments that can analyze small molecular weight contaminants in samples quickly and accurately and to the lowest limits of detection (LOD). Following a call to tender, which involved evaluation testing and result comparisons of a broad range of competitor products, the CVUA-MEL selected the Thermo Scientific Exactive benchtop MS coupled with the Transcend TLX system and DFS high resolution GC-MS systems. For information on how the systems help the CVUA-MEL ensure regulatory compliance, increase sample throughput and achieve greater sensitivity and improved accuracy, please see a detailed case study which is available to download: www.thermoscientific.com/fsnews
Tuesday 4 October 2011
Thermo Fisher Scientific Announces New Method for Precise and Reliable Analysis of Oil
ECUBLENS, Switzerland (October 3, 2011) – Thermo Fisher Scientific Inc., the world leader in serving science, today announced that it has developed a new precise and reliable method for elemental analysis of oil samples in the petrochemical industry. The innovative method uses the Thermo Scientific ARL PERFORM’X X-ray fluorescence (XRF) spectrometer to create a flexible and high-performance solution that is capable of reaching detection limits of below 0.5 parts per million (ppm). The new method, which covers a wide range of applications including the analysis of sulfur in oil and lead in gasoline, is detailed in an application note entitled “Analysis of Oils,” available to download free-of-charge via www.thermoscientific.com/performx.
Petrochemical regulations are becoming increasingly strict and are demanding lower levels of quantification for key elements such as sulfur, nickel, vanadium and lead in products. Compliance with various norms, including ASTM D2622, ASTM D4927 and ISO 20884, requires a method that can offer high sensitivity and stability to ensure content conforms to regulatory limits. The new Thermo Fisher method uses wavelength dispersive XRF (WDXRF), which is increasingly being used for analyses in the petroleum industry and has many advantages over traditional methods. This technique offers excellent repeatability and resolution, particularly for light elements such as sodium and calcium. In addition, it allows oils to be measured directly without dilution, which significantly reduces sample preparation time and increases speed and throughput of analyses.
Designed for demanding laboratories, the ARL PERFORM’X system offers dual sample loading and is able to process more than 60 samples per hour, offering rapid and precise analysis of up to 84 elements including sulfur, nickel, vanadium and lead. The instrument provides the highest standards of safety with an innovative sample recognition capability that ensures safe and straightforward loading of liquids. With its helium shutter, the ARL PERFORM’X completely protects the goniometer from chemical attacks and thermo instability by separating the primary chamber for the spectral chamber. The system also offers unmatched stability and repeatability of results, making it ideally suited to solving complex composition problems in demanding industrial applications.
The ARL PERFORM’X instrument features the latest version of the state-of-the-art Thermo Scientific OXSAS software, which is able to operate with Microsoft Windows® 7 to ensure simple and trouble-free analyses. Users also benefit from a synoptic panel that mimics real-time operation and internal functioning of the instrument on a separate display screen, enabling users to monitor the status of their analyses and improve productivity as a result of the software’s fast and accurate reporting capabilities.
For more information about the new Thermo Scientific ARL PERFORM’X and to obtain a copy of the new application note, please call +1 800-532-4752, email analyze@thermofisher.com or visit www.thermoscientific.com/performx.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science. Our mission is to enable our customers to make the world healthier, cleaner and safer. With revenues of nearly $11 billion, we have approximately 37,000 employees and serve customers within pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as in environmental and process control industries. We create value for our key stakeholders through two premier brands, Thermo Scientific and Fisher Scientific, which offer a unique combination of continuous technology development and the most convenient purchasing options. Our products and services help accelerate the pace of scientific discovery, and solve analytical challenges ranging from complex research to routine testing to field applications. Visit www.thermofisher.com.
###
Petrochemical regulations are becoming increasingly strict and are demanding lower levels of quantification for key elements such as sulfur, nickel, vanadium and lead in products. Compliance with various norms, including ASTM D2622, ASTM D4927 and ISO 20884, requires a method that can offer high sensitivity and stability to ensure content conforms to regulatory limits. The new Thermo Fisher method uses wavelength dispersive XRF (WDXRF), which is increasingly being used for analyses in the petroleum industry and has many advantages over traditional methods. This technique offers excellent repeatability and resolution, particularly for light elements such as sodium and calcium. In addition, it allows oils to be measured directly without dilution, which significantly reduces sample preparation time and increases speed and throughput of analyses.
Designed for demanding laboratories, the ARL PERFORM’X system offers dual sample loading and is able to process more than 60 samples per hour, offering rapid and precise analysis of up to 84 elements including sulfur, nickel, vanadium and lead. The instrument provides the highest standards of safety with an innovative sample recognition capability that ensures safe and straightforward loading of liquids. With its helium shutter, the ARL PERFORM’X completely protects the goniometer from chemical attacks and thermo instability by separating the primary chamber for the spectral chamber. The system also offers unmatched stability and repeatability of results, making it ideally suited to solving complex composition problems in demanding industrial applications.
The ARL PERFORM’X instrument features the latest version of the state-of-the-art Thermo Scientific OXSAS software, which is able to operate with Microsoft Windows® 7 to ensure simple and trouble-free analyses. Users also benefit from a synoptic panel that mimics real-time operation and internal functioning of the instrument on a separate display screen, enabling users to monitor the status of their analyses and improve productivity as a result of the software’s fast and accurate reporting capabilities.
For more information about the new Thermo Scientific ARL PERFORM’X and to obtain a copy of the new application note, please call +1 800-532-4752, email analyze@thermofisher.com or visit www.thermoscientific.com/performx.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science. Our mission is to enable our customers to make the world healthier, cleaner and safer. With revenues of nearly $11 billion, we have approximately 37,000 employees and serve customers within pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as in environmental and process control industries. We create value for our key stakeholders through two premier brands, Thermo Scientific and Fisher Scientific, which offer a unique combination of continuous technology development and the most convenient purchasing options. Our products and services help accelerate the pace of scientific discovery, and solve analytical challenges ranging from complex research to routine testing to field applications. Visit www.thermofisher.com.
###
Monday 3 October 2011
CHESHIRE B2B AGENCY THE SCOTT PARTNERSHIP ANNOUNCES SECOND ACQUISITION IN TWO MONTHS IN CONTINUED GROWTH STRATEGY
03 October 2011: Cheshire based B2B agency The Scott Partnership Ltd (www.scottpr.com) announces the acquisition of Cambridge-based scientific marketing agency Phoenix Marcom Ltd (www.phoenixmarcom.co.uk). The acquisition sees Phoenix move into the holding company of The Scott Partnership Ltd to operate as a wholly owned stand-alone business. The addition of Phoenix Marcom marks the second acquisition since July 2011 for Scott Partnership Holdings Ltd, as it continues to expand its offering in scientific markets with three strong autonomous brands.
CEO Kath Darlington explains "Phoenix Marcom is a strong, established business, with a solid record of scientific, full-service marketing in Europe. The company provides its clients with a broad portfolio of marketing services, and has an impressive customer base. Our intention is that Phoenix will remain autonomous, servicing its predominantly European clients, retaining its focus in the Cambridge area, via the existing Phoenix team. The founder of Phoenix Marcom, Paul Carter, will join The Scott Partnership to support our expansion in Europe. All five companies in Scott Partnership Holdings will now offer PR and marketing services, specializing in healthcare and life sciences markets worldwide."
Friday 30 September 2011
Novozymes enters into an exclusive supplier agreement to supply Recombumin for Type 2 Diabetes drug
NOTTINGHAM, UK – September 30, 2011 – Novozymes Biopharma, part of Novozymes A/S, a world leader in bioinnovation, has announced that it has concluded an exclusive supply agreement with ConjuChem LLC of Los Angeles, California. Novozymes will supply its recombinant human albumin, Recombumin, for use in the development of a new GLP-1 analog in Phase 2 testing for Type 2 diabetes. The use of Recombumin in the development of the product potentially significantly reduces dosing frequency, allowing patients to self-inject once per week instead of once or twice daily.
“This supply agreement is a great example of using Novozymes’ Recombumin as a vehicle for extending the half-life of peptides in drug delivery applications,” said Thomas Videbæk, Executive Vice President of Novozymes’ BioBusiness. “Also the agreement for this new drug will potentially pave the way for the use of Recombumin in other peptide-based therapies.”
Thursday 29 September 2011
EXCO INTOUCH SECURES GROWTH INVESTMENT FROM SEP
Mobile patient communication leader to use funds to accelerate growth strategy
LONDON, UK - 29 September, 2011 - Leading growth equity and venture capital group Scottish Equity Partners (SEP) has led an initial £3m pound investment in Exco InTouch, the leading provider of mobile patient communication and management solutions for the pharmaceutical and healthcare sector.
SEP has taken a minority stake in the company which will use the funds to accelerate its expansion, enabling it to take advantage of significant growth opportunities in the clinical technology sector, particularly in the emerging mobile patient communication market.
Tuesday 27 September 2011
Thermo Fisher Scientific Launches New Total Nitrogen and Sulfur Analyzer for Precise and Accurate Analysis of Petroleum Products Using a Single Introduction Module
CAMBRIDGE, UK (September 27, 2011) - Thermo Fisher Scientific Inc., the world leader in serving science, today announced the launch of a new Total Nitrogen and Total Sulfur (TN/TS) analyzer, which features an innovative direct injection design providing the capacity to analyze both heavy and light hydrocarbons without changing introduction modules. As a result of the versatility, precision and accuracy offered by the Thermo Scientific iPRO 5000 series analyzer, scientists in petrochemical and commercial testing laboratories, oil refineries, R&D centers and chemical plants, will benefit from significant time savings and productivity advantages, in addition to total ASTM compliance.
Subscribe to:
Posts (Atom)